|
FY 2018
|
Q4 2018
|
||||
$m
|
% change
|
$m
|
% change
|
|||
|
Actual
|
CER
|
Actual
|
CER
|
||
Product
Sales
|
21,049
|
4
|
4
|
5,768
|
5
|
8
|
Externalisation
Revenue
|
1,041
|
(55)
|
(55)
|
649
|
n/m
|
n/m
|
Total
Revenue
|
22,090
|
(2)
|
(2)
|
6,417
|
11
|
14
|
|
|
|
|
|
|
|
Reported
Operating Profit3
|
3,387
|
(8)
|
(7)
|
1,077
|
57
|
54
|
Core
Operating Profit4
|
5,672
|
(17)
|
(17)
|
2,192
|
23
|
23
|
|
|
|
|
|
|
|
Reported
Earnings Per Share (EPS)
|
$1.70
|
(28)
|
(29)
|
$0.82
|
(21)
|
(22)
|
Core
EPS
|
$3.46
|
(19)
|
(19)
|
$1.58
|
22
|
22
|
Regulatory
approvals
|
- Lynparza -
ovarian cancer (1st line) (SOLO-1): regulatory approval
(US)
- roxadustat
- anaemia in dialysis patients: regulatory approval
(CN)
- Bevespi -
COPD10:
regulatory approval (EU)
- Linzess (linaclotide)
- inflammatory bowel syndrome w/constipation (IBS-C): regulatory
approval (CN)
|
Regulatory
submissions and/or acceptances
|
- Imfinzi -
unresectable, Stage III NSCLC: regulatory submission (CN);
acceptance (OS11 data)
(US)
- Farxiga -
type-1 diabetes: regulatory submission acceptance (US)
- Fasenra -
severe, eosinophilic asthma; self-administration:
submission
acceptance (US,
EU)
|
Major
Phase III data readouts or other significant
developments
|
- Tagrisso -
EGFRm NSCLC (1st line): priority review (CN)
- Imfinzi +/-
treme - NSCLC (1st line) (MYSTIC): did not meet OS primary
endpoints
- Imfinzi +/-
treme - head & neck cancer (2nd line): did not meet OS primary
endpoints
- Lynparza -
ovarian cancer (1st line) (SOLO-1): priority review
(CN)
- Lynparza -
ovarian cancer (3rd line+): met response rate
primary endpoint
- Forxiga -
type-1 diabetes: CHMP12 positive
opinion (EU)
- roxadustat
- anaemia of CKD13: met primary
efficacy endpoints
- Fasenra -
eosinophilic granulomatosis with polyangiitis: Orphan Drug
Designation (US)
- Fasenra -
hypereosinophilic syndrome: Orphan Drug Designation
(US)
- PT010
- COPD: priority review (CN)
- MEDI8897-
lower respiratory tract infection: Breakthrough Therapy Designation
(US), PRIME14designation
(EU)
|
Product Sales
|
A high
single-digit percentage increase
|
Core EPS
|
$3.50
to $3.70
|
H1
2019
|
- Tagrisso -
EGFRm NSCLC (1st line): regulatory decision (CN)
- Imfinzi +/-
treme - head & neck cancer (1st line): data readout, regulatory
submission
- Lynparza -
breast cancer: regulatory decision (EU)
- Lynparza -
pancreatic cancer: data readout
- Brilinta -
CAD[15] /
type-2 diabetes CVOT[16]:
data readout
- Forxiga -
type-1 diabetes: regulatory decision (EU,
JP)
- Farxiga -
type-2 diabetes CVOT: regulatory submission
- roxadustat
- anaemia: data readout (pooled safety), regulatory submission
(US)
- Duaklir -
COPD: regulatory decision (US)
|
H2
2019
|
- Tagrisso -
EGFRm NSCLC (1st line): data readout (final OS)
- Imfinzi -
unresectable, Stage III NSCLC: regulatory decision
(CN)
- Imfinzi +
treme - NSCLC (1st line) (NEPTUNE): data readout, regulatory
submission
- Imfinzi +/-
treme - NSCLC (1st line) (POSEIDON): data readout, regulatory
submission
- Imfinzi +/-
treme - small-cell lung cancer: data readout, regulatory
submission
- Imfinzi +/-
treme - bladder cancer (1st line): data readout, regulatory
submission
- Lynparza -
ovarian cancer (1st line) (SOLO-1): regulatory decision (EU, JP,
CN)
- Lynparza -
pancreatic cancer: regulatory submission
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): data readout
- Lynparza -
prostate cancer (2nd line, castration-resistant): data
readout
- Calquence -
CLL[17]:
data readout, regulatory submission
- selumetinib
- NF1: regulatory submission
- Brilinta -
CAD / type-2 diabetes CVOT: regulatory submission
- Farxiga -
type-1 diabetes: regulatory decision (US)
- Lokelma -
hyperkalaemia: regulatory submission (JP)
- Symbicort -
mild asthma: regulatory decision (EU), regulatory submission
(CN)
- Bevespi -
COPD: regulatory decision (JP, CN)
- Fasenra -
self administration: regulatory decision (US, EU)
- PT010
- COPD: regulatory decision (JP, CN), regulatory submission (US,
EU)
- PT010
- COPD: data readout (ETHOS)
|
2020
|
- Imfinzi -
neo-adjuvant NSCLC: data readout
- Lynparza -
ovarian cancer (1st line) (PAOLA-1): regulatory
submission
- Lynparza -
prostate cancer (2nd line, castration-resistant): regulatory
submission
- Brilinta -
stroke: data readout, regulatory submission
- Farxiga -
heart failure CVOT: data readout, regulatory
submission
- Farxiga -
CKD: data readout
- Epanova -
hypertriglyceridaemia CVOT: data readout
- Lokelma -
hyperkalaemia: regulatory submission (CN)
- roxadustat
- anaemia of myelodysplastic syndrome: data readout
- Fasenra -
nasal polyps: data readout, regulatory submission
- tezepelumab
- severe asthma: data readout
|
Investor
Relations
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203
749 5712
|
Henry
Wheeler
|
Oncology
|
+44 203
749 5797
|
Christer
Gruvris
|
BioPharma
-
Cardiovascular;
Metabolism
|
+44 203
749 5711
|
Nick
Stone
|
BioPharma
-
Respiratory;
Renal
|
+44 203
749 5716
|
Josie
Afolabi
|
Other
|
+44 203
749 5631
|
Craig
Marks
|
Finance;
Fixed Income
|
+44
7881 615 764
|
Jennifer
Kretzmann
|
Retail
Investors; Corporate Access
|
+44 203
749 5824
|
US
toll-free
|
|
+1 866
381 7277
|
Media
Relations
|
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203
749 5916
|
Rob
Skelding
|
UK/Global
|
+44 203
749 5821
|
Matt
Kent
|
UK/Global
|
+44 203
749 5906
|
Jennifer
Hursit
|
UK/Global
|
+44
7384 799 726
|
Christina Malmberg
Hägerstrand
|
Sweden
|
+46 8 552 53 106
|
Michele
Meixell
|
US
|
+1 302
885 2677
|
|
FY 2018
|
Q4 2018
|
||||
$m
|
% change
|
$m
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||
Product
Sales
|
21,049
|
4
|
4
|
5,768
|
5
|
8
|
Externalisation
Revenue
|
1,041
|
(55)
|
(55)
|
649
|
n/m
|
n/m
|
|
|
|
|
|
|
|
Total Revenue
|
22,090
|
(2)
|
(2)
|
6,417
|
11
|
14
|
|
FY 2018
|
Q4 2018
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Oncology
|
6,028
|
29
|
50
|
49
|
1,767
|
31
|
58
|
61
|
New
CVRM
|
4,004
|
19
|
12
|
12
|
1,103
|
19
|
8
|
11
|
Respiratory
|
4,911
|
23
|
4
|
3
|
1,362
|
24
|
2
|
5
|
Other
|
6,106
|
29
|
(22)
|
(23)
|
1,536
|
27
|
(24)
|
(21)
|
|
|
|
|
|
|
|
|
|
Total
|
21,049
|
100
|
4
|
4
|
5,768
|
100
|
5
|
8
|
Medicine
|
Therapy Area
|
$m
|
% of Total Product Sales
|
Symbicort
|
Respiratory
|
2,561
|
12
|
Tagrisso
|
Oncology
|
1,860
|
9
|
Nexium
|
Other
|
1,702
|
8
|
Crestor
|
CVRM
|
1,433
|
7
|
Farxiga
|
CVRM
|
1,391
|
7
|
Brilinta
|
CVRM
|
1,321
|
6
|
Pulmicort
|
Respiratory
|
1,286
|
6
|
Faslodex
|
Oncology
|
1,028
|
5
|
Zoladex
|
Oncology
|
752
|
4
|
Seloken/Toprol-XL
|
CVRM
|
712
|
3
|
|
|
|
|
Total
|
|
14,046
|
67
|
|
FY 2018
|
Q4 2018
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
Actual
|
CER
|
|||||
Initial Externalisation Revenue
|
112
|
11
|
(93)
|
(93)
|
-
|
-
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Royalties
|
49
|
5
|
(54)
|
(54)
|
11
|
2
|
45
|
41
|
Milestones/Other[18]
|
880
|
84
|
24
|
23
|
638
|
98
|
n/m
|
n/m
|
Ongoing Externalisation Revenue
|
929
|
89
|
14
|
13
|
649
|
100
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Total Externalisation Revenue
|
1,041
|
100
|
(55)
|
(55)
|
649
|
100
|
n/m
|
n/m
|
Medicine
|
Party
|
Region
|
$m
|
Crestor
|
Almirall,
S.A.
|
Spain
|
61
|
Other
|
|
|
51
|
|
|
|
|
Total
|
|
|
112
|
Medicine
|
Party
|
Region
|
$m
|
Lynparza
|
MSD
- milestone revenue
(regulatory)
|
Global
|
140
|
Lynparza
|
MSD -
milestone revenue
(sales-related)
|
Global
|
250
|
Lynparza
|
MSD
- milestone revenue
(option
payment)
|
Global
|
400
|
Other
|
|
|
139
|
|
|
|
|
Total
|
|
|
929
|
Completion
|
Medicine
|
Region
|
FY 2018[19]
|
FY 2017
|
Adverse Impact on
FY 2018
Product Sales
|
|
$m
|
$m
|
$m
|
%
|
|||
January
2018
|
Crestor
|
Spain
|
7
|
74
|
(67)
|
|
June
2018
|
Seroquel XRand
Seroquel IR
|
UK,
China and other countries
|
109
|
148
|
(39)
|
|
September
2018
|
Atacand
|
Europe
|
70
|
86
|
(16)
|
|
November
2018
|
Nexium andVimovo
|
Europe,
Global
|
235
|
248
|
(13)
|
|
|
|
|
|
|
|
|
|
Total
|
|
421
|
556
|
(135)
|
2%
|
Therapy Area
|
Medicine
|
FY 2018
|
|||
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
1,860
|
9
|
95
|
93
|
Lynparza
|
647
|
3
|
n/m
|
n/m
|
|
Imfinzi
|
633
|
3
|
n/m
|
n/m
|
|
Iressa
|
518
|
2
|
(2)
|
(4)
|
|
Calquence
|
62
|
-
|
n/m
|
n/m
|
|
LEGACY:
|
|
|
|
|
|
Faslodex
|
1,028
|
5
|
9
|
9
|
|
Zoladex
|
752
|
4
|
2
|
2
|
|
Arimidex
|
212
|
1
|
(2)
|
(3)
|
|
Casodex
|
201
|
1
|
(7)
|
(8)
|
|
Others
|
115
|
1
|
1
|
(1)
|
|
Total Oncology
|
6,028
|
29
|
50
|
49
|
|
CVRM
|
Farxiga
|
1,391
|
7
|
30
|
30
|
Brilinta
|
1,321
|
6
|
22
|
21
|
|
Bydureon
|
584
|
3
|
2
|
1
|
|
Onglyza
|
543
|
3
|
(11)
|
(11)
|
|
Byetta
|
126
|
1
|
(28)
|
(28)
|
|
Symlin
|
34
|
-
|
(29)
|
(29)
|
|
LEGACY:
|
|
|
|
|
|
Crestor
|
1,433
|
7
|
(39)
|
(40)
|
|
Seloken/Toprol-XL
|
712
|
3
|
2
|
4
|
|
Atacand
|
260
|
1
|
(13)
|
(12)
|
|
Others
|
306
|
1
|
(11)
|
(12)
|
|
Total CVRM
|
6,710
|
32
|
(8)
|
(8)
|
|
Respiratory
|
Symbicort
|
2,561
|
12
|
(9)
|
(10)
|
Pulmicort
|
1,286
|
6
|
9
|
8
|
|
Fasenra
|
297
|
1
|
n/m
|
n/m
|
|
Daliresp/Daxas
|
189
|
1
|
(5)
|
(5)
|
|
Tudorza/Eklira
|
110
|
1
|
(27)
|
(29)
|
|
Duaklir
|
95
|
-
|
20
|
14
|
|
Bevespi
|
33
|
-
|
n/m
|
n/m
|
|
Others
|
340
|
2
|
20
|
18
|
|
Total Respiratory
|
4,911
|
23
|
4
|
3
|
|
Other
|
Nexium
|
1,702
|
8
|
(13)
|
(14)
|
Synagis
|
665
|
3
|
(3)
|
(3)
|
|
Seroquel XR/IR
|
361
|
2
|
(29)
|
(31)
|
|
Losec/Prilosec
|
272
|
1
|
-
|
(2)
|
|
FluMist/Fluenz
|
110
|
1
|
41
|
44
|
|
Movantik/Moventig
|
109
|
1
|
(11)
|
(11)
|
|
Others
|
181
|
1
|
(66)
|
(67)
|
|
Total Other
|
3,400
|
16
|
(18)
|
(19)
|
|
|
Total Product Sales
|
21,049
|
100
|
4
|
4
|
Therapy Area
|
Medicine
|
Q4 2018
|
|||
$m
|
% of total
|
% change
|
|||
Actual
|
CER
|
||||
Oncology
|
Tagrisso
|
594
|
10
|
95
|
98
|
Lynparza
|
209
|
4
|
n/m
|
n/m
|
|
Imfinzi
|
262
|
5
|
n/m
|
n/m
|
|
Iressa
|
112
|
2
|
(14)
|
(11)
|
|
Calquence
|
24
|
-
|
n/m
|
n/m
|
|
LEGACY:
|
|
|
|
|
|
Faslodex
|
269
|
5
|
13
|
16
|
|
Zoladex
|
182
|
3
|
(3)
|
3
|
|
Arimidex
|
46
|
1
|
(19)
|
(16)
|
|
Casodex
|
46
|
1
|
(15)
|
(13)
|
|
Others
|
23
|
-
|
(21)
|
(17)
|
|
Total Oncology
|
1,767
|
31
|
58
|
61
|
|
CVRM
|
Farxiga
|
397
|
7
|
20
|
24
|
Brilinta
|
376
|
7
|
26
|
29
|
|
Bydureon
|
138
|
2
|
(6)
|
(5)
|
|
Onglyza
|
148
|
3
|
(18)
|
(15)
|
|
Byetta
|
32
|
1
|
(33)
|
(31)
|
|
Symlin
|
10
|
-
|
(23)
|
(23)
|
|
LEGACY:
|
|
|
|
|
|
Crestor
|
353
|
6
|
(41)
|
(38)
|
|
Seloken/Toprol-XL
|
160
|
3
|
(5)
|
4
|
|
Atacand
|
58
|
1
|
(21)
|
(14)
|
|
Others
|
75
|
1
|
(12)
|
(8)
|
|
Total CVRM
|
1,747
|
30
|
(10)
|
(6)
|
|
Respiratory
|
Symbicort
|
636
|
11
|
(15)
|
(13)
|
Pulmicort
|
389
|
7
|
5
|
9
|
|
Fasenra
|
125
|
2
|
n/m
|
n/m
|
|
Daliresp/Daxas
|
54
|
1
|
2
|
4
|
|
Tudorza/Eklira
|
19
|
-
|
(55)
|
(55)
|
|
Duaklir
|
22
|
-
|
(4)
|
-
|
|
Bevespi
|
10
|
-
|
25
|
25
|
|
Others
|
107
|
2
|
26
|
32
|
|
Total Respiratory
|
1,362
|
24
|
2
|
5
|
|
Other
|
Nexium
|
390
|
7
|
(9)
|
(6)
|
Synagis
|
251
|
4
|
7
|
7
|
|
FluMist/Fluenz
|
75
|
1
|
29
|
33
|
|
Losec/Prilosec
|
60
|
1
|
(13)
|
(9)
|
|
Seroquel XR/IR
|
56
|
1
|
(65)
|
(64)
|
|
Movantik/Moventig
|
25
|
-
|
(17)
|
(17)
|
|
Others
|
35
|
1
|
(70)
|
(68)
|
|
Total Other
|
892
|
15
|
(18)
|
(17)
|
|
Total Product Sales
|
5,768
|
100
|
5
|
8
|
|
FY 2018
|
Q4 2018
|
|||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
||||
Actual
|
CER
|
Actual
|
CER
|
||||||
Emerging Markets[20]
|
6,891
|
33
|
12
|
13
|
1,766
|
31
|
8
|
16
|
|
China
|
3,795
|
18
|
28
|
25
|
948
|
16
|
17
|
22
|
|
Ex-China
|
3,096
|
15
|
(3)
|
1
|
818
|
14
|
-
|
10
|
|
|
|
|
|
|
|
|
|
|
|
US
|
6,876
|
33
|
11
|
11
|
2,037
|
35
|
15
|
15
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,459
|
21
|
(6)
|
(10)
|
1,173
|
20
|
(9)
|
(7)
|
|
|
|
|
|
|
|
|
|
|
|
Established
ROW
|
2,823
|
13
|
(8)
|
(9)
|
792
|
14
|
-
|
1
|
|
Japan
|
2,004
|
10
|
(9)
|
(11)
|
588
|
10
|
4
|
5
|
|
Canada
|
489
|
2
|
1
|
-
|
131
|
2
|
-
|
4
|
|
Other Established ROW
|
330
|
2
|
(15)
|
(14)
|
73
|
1
|
(27)
|
(22)
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
21,049
|
100
|
4
|
4
|
5,768
|
100
|
5
|
8
|
|
FY 2018 |
Q4
2018
|
||||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
|||||||
Oncology
|
1,528
|
22
|
36
|
37
|
355
|
20
|
19
|
30
|
||
CVRM
|
2,695
|
39
|
14
|
15
|
691
|
39
|
12
|
21
|
||
Respiratory
|
1,644
|
24
|
18
|
18
|
497
|
28
|
17
|
25
|
||
Other
|
1,024
|
15
|
(19)
|
(19)
|
223
|
13
|
(23)
|
(21)
|
||
|
|
|
|
|
|
|
|
|
||
Total
|
6,891
|
100
|
12
|
13
|
1,766
|
100
|
8
|
16
|
|
FY 2018
|
Q4 2018
|
||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|
Oncology
|
2,412
|
35
|
n/m
|
792
|
39
|
134
|
CVRM
|
2,206
|
32
|
(7)
|
604
|
30
|
(14)
|
Respiratory
|
1,416
|
21
|
(6)
|
386
|
19
|
(6)
|
Other
|
842
|
12
|
(28)
|
255
|
12
|
(20)
|
|
|
|
|
|
|
|
Total
|
6,876
|
100
|
11
|
2,037
|
100
|
15
|
|
FY 2018
|
Q4 2018
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||
|
|
Actual
|
CER
|
|
Actual
|
CER
|
||
Oncology
|
1,053
|
24
|
19
|
14
|
287
|
25
|
19
|
21
|
CVRM
|
1,230
|
27
|
(26)
|
(29)
|
295
|
25
|
(28)
|
(26)
|
Respiratory
|
1,229
|
28
|
1
|
(4)
|
307
|
26
|
(9)
|
(7)
|
Other
|
947
|
21
|
(5)
|
(8)
|
284
|
24
|
(6)
|
(3)
|
|
|
|
|
|
|
|
|
|
Total
|
4,459
|
100
|
(6)
|
(10)
|
1,173
|
100
|
(9)
|
(7)
|
|
FY 2018 | Q4 2018 |
|
|
||||||
$m
|
% of total
|
% change
|
$m
|
% of total
|
% change
|
|||||
Actual
|
CER
|
Actual
|
CER
|
|||||||
Oncology
|
1,035
|
37
|
16
|
14
|
333
|
42
|
38
|
38
|
||
CVRM
|
579
|
21
|
(33)
|
(34)
|
157
|
20
|
(24)
|
(22)
|
||
Respiratory
|
622
|
22
|
5
|
4
|
172
|
22
|
6
|
8
|
||
Other
|
587
|
21
|
(19)
|
(20)
|
130
|
16
|
(29)
|
(27)
|
||
|
|
|
|
|
|
|
|
|
||
Total
|
2,823
|
100
|
(8)
|
(9)
|
792
|
100
|
-
|
1
|
|
Reported
|
|||
FY 2018
|
FY 2017
|
% change
|
||
$m
|
$m
|
Actual
|
CER
|
|
Product
Sales
|
21,049
|
20,152
|
4
|
4
|
Externalisation
Revenue
|
1,041
|
2,313
|
(55)
|
(55)
|
Total
Revenue
|
22,090
|
22,465
|
(2)
|
(2)
|
|
|
|
|
|
Cost of
Sales
|
(4,936)
|
(4,318)
|
14
|
13
|
|
|
|
|
|
Gross
Profit
|
17,154
|
18,147
|
(5)
|
(6)
|
Gross Margin[21]
|
76.6%
|
79.6%
|
-3
|
-3
|
|
|
|
|
|
Distribution
Expense
|
(331)
|
(310)
|
7
|
6
|
% Total Revenue
|
1.5%
|
1.4%
|
-
|
-
|
R&D
Expense
|
(5,932)
|
(5,757)
|
3
|
3
|
% Total Revenue
|
26.9%
|
25.6%
|
-1
|
-1
|
SG&A
Expense
|
(10,031)
|
(10,233)
|
(2)
|
(3)
|
% Total Revenue
|
45.4%
|
45.5%
|
-
|
-
|
Other
Operating Income and Expense
|
2,527
|
1,830
|
38
|
38
|
% Total Revenue
|
11.4%
|
8.1%
|
+3
|
+3
|
|
|
|
|
|
Operating
Profit
|
3,387
|
3,677
|
(8)
|
(7)
|
% Total Revenue
|
15.3%
|
16.4%
|
-1
|
-1
|
Net
Finance Expense
|
(1,281)
|
(1,395)
|
(8)
|
2
|
Joint
Ventures and Associates
|
(113)
|
(55)
|
n/m
|
n/m
|
Profit
Before Tax
|
1,993
|
2,227
|
(10)
|
(14)
|
Taxation
|
57
|
641
|
|
|
Tax
Rate
|
(3)%
|
(29)%
|
|
|
Profit
After Tax
|
2,050
|
2,868
|
(29)
|
(30)
|
|
|
|
|
|
Earnings
Per Share
|
$1.70
|
$2.37
|
(28)
|
(29)
|
|
Reported
|
||||
Q4 2018
|
Q4 2017
|
% change
|
|||
$m
|
$m
|
Actual
CER
|
|||
Product
Sales
|
5,768
|
5,487
|
5
|
8
|
|
Externalisation
Revenue
|
649
|
290
|
n/m
|
n/m
|
|
Total
Revenue
|
6,417
|
5,777
|
11
|
14
|
|
|
|
|
|
|
|
Cost of
Sales
|
(1,637)
|
(1,225)
|
34
|
37
|
|
|
|
|
|
|
|
Gross
Profit
|
4,780
|
4,552
|
5
|
8
|
|
Gross Margin[22]
|
71.6%
|
77.6%
|
-6
|
-6
|
|
|
|
|
|
|
|
Distribution
Expense
|
(93)
|
(85)
|
10
|
16
|
|
% Total Revenue
|
1.5%
|
1.5%
|
-
|
-
|
|
R&D
Expense
|
(2,012)
|
(1,551)
|
30
|
33
|
|
% Total Revenue
|
31.4%
|
26.8%
|
-4
|
-4
|
|
SG&A
Expense
|
(2,600)
|
(3,078)
|
(16)
|
(12)
|
|
% Total Revenue
|
40.5%
|
53.3%
|
+13
|
+12
|
|
Other
Operating Income & Expense
|
1,002
|
848
|
18
|
19
|
|
% Total Revenue
|
15.6%
|
14.7%
|
+1
|
+1
|
|
|
|
|
|
|
|
Operating
Profit
|
1,077
|
686
|
57
|
54
|
|
% Total Revenue
|
16.8%
|
11.9%
|
+5
|
+4
|
|
Net
Finance Expense
|
(311)
|
(267)
|
17
|
24
|
|
Joint
Ventures and Associates
|
(36)
|
(12)
|
n/m
|
n/m
|
|
Profit
Before Tax
|
730
|
407
|
79
|
69
|
|
Taxation
|
279
|
854
|
|
|
|
Tax
Rate
|
(38)%
|
(210)%
|
|
|
|
Profit
After Tax
|
1,009
|
1,261
|
(20)
|
(22)
|
|
|
|
|
|
|
|
Earnings
Per Share
|
$0.82
|
$1.03
|
(21)
|
(22)
|
|
|
|
|
|
|
|
|
FY 2018 $m
|
FY 2017 $m
|
% change
|
|
Actual
|
CER
|
|||
Reported
Profit Before Tax
|
1,993
|
2,227
|
(10)
|
(14)
|
Net
Finance Expense
|
1,281
|
1,395
|
(8)
|
2
|
Joint
Ventures and Associates
|
113
|
55
|
n/m
|
n/m
|
Depreciation,
Amortisation and Impairment
|
3,753
|
3,036
|
24
|
24
|
|
|
|
|
|
EBITDA
|
7,140
|
6,713
|
6
|
7
|
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other[24]
|
Core[25]
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross
Profit
|
17,154
|
432
|
187
|
-
|
-
|
17,773
|
(4)
|
(4)
|
Gross Margin[26]
|
76.6%
|
-
|
-
|
-
|
-
|
79.5%
|
-2
|
-2
|
|
|
|
|
|
|
|
|
|
Distribution
Expense
|
(331)
|
-
|
-
|
-
|
-
|
(331)
|
7
|
6
|
R&D
Expense
|
(5,932)
|
94
|
572
|
-
|
-
|
(5,266)
|
(3)
|
(3)
|
SG&A
Expense
|
(10,031)
|
181
|
1,582
|
(60)
|
(323)
|
(8,651)
|
10
|
9
|
Other
Operating Income & Expense
|
2,527
|
(10)
|
4
|
-
|
(374)
|
2,147
|
10
|
10
|
|
|
|
|
|
|
|
|
|
Operating
Profit
|
3,387
|
697
|
2,345
|
(60)
|
(697)
|
5,672
|
(17)
|
(17)
|
% Total Revenue
|
15.3%
|
-
|
-
|
-
|
-
|
25.7%
|
-5
|
-5
|
|
|
|
|
|
|
|
|
|
Net
Finance Expense
|
(1,281)
|
-
|
-
|
337
|
208
|
(736)
|
13
|
11
|
Taxation
|
57
|
(146)
|
(487)
|
(73)
|
109
|
(540)
|
(37)
|
(36)
|
|
|
|
|
|
|
|
|
|
Earnings
Per Share
|
$1.70
|
$0.43
|
$1.47
|
$0.16
|
$(0.30)
|
$3.46
|
(19)
|
(19)
|
|
Reported
|
Restructuring
|
Intangible Asset
Amortisation & Impairments
|
Diabetes Alliance
|
Other[27]
|
Core[28]
|
Core
% change
|
|
$m
|
$m
|
$m
|
$m
|
$m
|
$m
|
Actual
|
CER
|
|
Gross
Profit
|
4,780
|
355
|
48
|
-
|
-
|
5,183
|
11
|
14
|
Gross Margin[29]
|
71.6%
|
-
|
-
|
-
|
-
|
78.6%
|
(1)
|
(1)
|
|
|
|
|
|
|
|
|
|
Distribution
Expense
|
(93)
|
-
|
-
|
-
|
-
|
(93)
|
10
|
16
|
R&D
Expense
|
(2,012)
|
(1)
|
547
|
-
|
-
|
(1,466)
|
1
|
3
|
SG&A
Expense
|
(2,600)
|
71
|
515
|
(380)
|
(42)
|
(2,436)
|
12
|
15
|
Other
Operating Income & Expense
|
1,002
|
1
|
1
|
-
|
-
|
1,004
|
18
|
18
|
|
|
|
|
|
|
|
|
|
Operating
Profit
|
1,077
|
426
|
1,111
|
(380)
|
(42)
|
2,192
|
23
|
23
|
% Total Revenue
|
16.8%
|
-
|
-
|
-
|
-
|
34.2%
|
3
|
3
|
|
|
|
|
|
|
|
|
|
Net
Finance Expense
|
(311)
|
-
|
-
|
84
|
52
|
(175)
|
43
|
41
|
Taxation
|
279
|
(89)
|
(238)
|
47
|
5
|
4
|
n/m
|
n/m
|
|
|
|
|
|
|
|
|
|
Earnings
Per Share
|
$0.82
|
$0.26
|
$0.69
|
$(0.20)
|
$0.01
|
$1.58
|
22
|
22
|
|
FY 2018
|
FY 2017
|
Change
|
$m
|
$m
|
$m
|
|
Reported
Operating Profit
|
3,387
|
3,677
|
(290)
|
Depreciation,
Amortisation and Impairment
|
3,753
|
3,036
|
717
|
|
|
|
|
Increase
in Working Capital and Short-Term Provisions
|
(639)
|
(50)
|
(589)
|
Gains
on Disposal of Intangible Assets
|
(1,885)
|
(1,518)
|
(367)
|
Non-Cash
and Other Movements
|
(785)
|
(415)
|
(370)
|
Interest
Paid
|
(676)
|
(698)
|
22
|
Tax
Paid
|
(537)
|
(454)
|
(83)
|
|
|
|
|
Net Cash Inflow from Operating Activities
|
2,618
|
3,578
|
(960)
|
|
|
|
|
Net Cash Inflow/(Outflow) from Investing Activities
|
963
|
(2,328)
|
3,291
|
|
|
|
|
Net Cash Outflows from Financing Activities
|
(2,044)
|
(2,936)
|
892
|
|
At 31 Dec 2018
|
At 31 Dec 2017
|
$m
|
$m
|
|
Cash
and Cash Equivalents
|
4,831
|
3,324
|
Other
Investments
|
895
|
1,300
|
|
|
|
Cash and Investments
|
5,726
|
4,624
|
|
|
|
Overdrafts
and Short-Term Borrowings
|
(755)
|
(845)
|
Finance
Leases
|
-
|
(5)
|
Current
Instalments of Loans
|
(999)
|
(1,397)
|
Loans
Due After One Year
|
(17,359)
|
(15,560)
|
|
|
|
Interest-Bearing Loans and Borrowings
(Gross Debt)
|
(19,113)
|
(17,807)
|
|
|
|
Net
Derivatives
|
384
|
504
|
Net Debt
|
(13,003)
|
(12,679)
|
|
Average ExchangeRates vs. USD
|
|
Annual Impact Of 5% Strengthening in Exchange Rate vs. USD
($m)[30]
|
|||
Currency
|
Primary Relevance
|
FY 2018[31]
|
YTD 2019[32]
|
% change
|
Product Sales
|
Core Operating Profit
|
CNY
|
Product
Sales
|
6.62
|
6.80
|
-3
|
+221
|
+126
|
EUR
|
Product
Sales
|
0.85
|
0.88
|
-3
|
+145
|
+66
|
JPY
|
Product
Sales
|
110.45
|
108.87
|
+1
|
+114
|
+74
|
Other[33]
|
|
|
|
|
+216
|
+105
|
|
|
|
|
|
|
|
GBP
|
Operating
Expenses
|
0.75
|
0.78
|
-4
|
+26
|
-72
|
SEK
|
Operating
Expenses
|
8.69
|
8.98
|
-3
|
+4
|
-73
|
Target
|
Plan year
|
Performance in the period
|
Reach
25m patients through AstraZeneca's portfolio of access
programmes
|
2025
|
On plan: AstraZeneca has reached more than 10 million
patients through its portfolio of Access to Healthcare programmes
(hHF, Phakamisa and Healthy Lung Asia). The Company recently
expanded the Healthy Lung programme as mentioned above
|
Lead
the industry to manage pharmaceuticals in the
environment
|
2025
|
On plan: ecopharmacovigilance (EPV) spatial
environmental risk-map updates have been commissioned and
product-specific concentration (measured vs. predicted safe)
distributions
are
being developed. These will form the basis
for a
first published EPV report
AstraZeneca's Pharmaceuticals in the Environmentstatement was published during the
period
|
Ensure
90% of active pharmaceutical ingredient syntheses meet
resource-efficiency targets at launch
|
2025
|
Lagging: overall reduction in H1 2018, with a 2%
decline across the Company's portfolio
|
Develop
resource-efficiency targets for biological medicines
|
2025
|
Lagging: positive developments on benchmarking
biologics process resource efficiency data through the American
Chemical Society Green Chemistry Institute Pharmaceutical
Roundtable. Behind plan on development of target
creation
|
Develop
a medicine-sustainability index and pilot approach
|
2019
|
On plan: project launched to develop a medicine
environmental-sustainability rating system, to be piloted
internally prior to external publication in 2019
|
Achieve
Science Based Targets for greenhouse gas emissions
|
2025
|
On plan: AstraZeneca's Operational Green House Gas
footprint declined by 4% vs. year-to-date 2015
Scope 1
-6%
Scope 2
-48%
Scope 3 emissions +11%[36]
|
100%
renewable-power consumption globally by 2025; interim ambition of
100% in the US and Europe by 2020
|
2025
|
On plan: 60% of sites already powered
by
renewable energy
|
Reduce
energy consumption by 10% against a 2015 baseline
|
2025
|
On plan: energy consumption increased by
2%
compared with 2015
|
Expand
the number of 'green-fleet' vehicles
|
2025
|
On plan: a number of European locations are
implementing green-fleet vehicles through their 'Green Mobility'
programmes. AstraZeneca US launched the 'GoGreen' initiative and it
is expected that by 2022, the Companies entire US fleet will be
made up of hybrid vehicles
|
Maintain
water usage as the business grows against a 2015
baseline
|
2025
|
Lagging: water use declined by 5% vs.
2015.
Water
audits and energy efficiency projects have driven large reductions
and cost savings. A warm summer for many of AstraZeneca's key
sites, however, contributed to higher than expected usage during
the period
|
Reduce
waste 10% below the 2015 baseline
|
2025
|
On plan: waste generated: -3% vs. 2015
Hazardous
waste: -3%
Non-hazardous
waste: -7%
An
increase in hazardous waste generation offset by reductions in
non-hazardous volumes. Target currently on track despite quarterly
fluctuations
|
Regulatory
approvals
|
4
|
- Lynparza -
ovarian cancer (1st line) (SOLO-1): regulatory approval
(US)
- roxadustat
- anaemia in dialysis patients: regulatory approval
(CN)
- Bevespi -
COPD: regulatory approval (EU)
- Linzess (linaclotide)
(IBS-C): regulatory approval (CN)
|
Regulatory
submissions and/or acceptances
|
5
|
- Imfinzi -
unresectable, Stage III NSCLC: regulatory submission (CN);
acceptance (OS data) (US)
- Farxiga -
type-1 diabetes: regulatory submission acceptance (US)
- Fasenra -
severe, eosinophilic asthma; self-administration:
submission
- acceptance
(US, EU)
|
Major
Phase III data readouts or other major developments
|
11
|
- Tagrisso -
EGFRm NSCLC (1st line): priority review (CN)
- Imfinzi +/-
treme - NSCLC (1st line) (MYSTIC): did not meet OS primary
endpoints
- Imfinzi +/-
treme - head & neck cancer (2nd line): did not meet OS primary
endpoints
- Lynparza -
ovarian cancer (1st line) (SOLO-1): priority review
(CN)
- Lynparza -
ovarian cancer (3rd line+): met response rate
primaryendpoint
- Forxiga -
type-1 diabetes: CHMP positive opinion (EU)
- roxadustat
- anaemia of CKD: met primary efficacy endpoints
- Fasenra -
eosinophilic granulomatosis with polyangiitis: Orphan Drug
Designation (US)
- Fasenra -
hypereosinophilic syndrome: Orphan Drug Designation
(US)
- PT010
- COPD: priority review (CN)
- MEDI8897
- lower respiratory tract infection: Breakthrough Therapy
Designation (US), PRIME designation (EU)
|
New
molecular entities and major lifecycle medicines in Phase III
trials or under regulatory review
|
11
|
Oncology
- Tagrisso -
NSCLC[37]
- Imfinzi -
multiple cancers37
- Lynparza -
multiple cancers37
- Calquence -
blood cancers36
- tremelimumab
- multiple cancers
- selumetinib -
NF1[38]
- savolitinib
- multiple cancers
CVRM
- roxadustat
- anaemia36
Respiratory
- PT010
- COPD36
- tezepelumab
- severe asthma
Other (outside main therapy
areas)
- anifrolumab
- lupus
|
Total
projects in clinical pipeline
|
131
|
|
|
Imfinzi
(n=163)
|
Chemotherapy
(n=162)
|
OS (primary endpoint) in PD-L1 ≥25%a
|
|
|
Number
of deaths (%)
|
108
(66.3%)
|
128
(79.0%)
|
HR
(97.54% CI)b,c
|
0.76
(0.564, 1.019)
|
|
p-valueb,d
|
0.036
|
|
Median
in months (95% CI)
|
16.3
(12.2, 20.8)
|
12.9
(10.5, 15.0)
|
24-month
OS rate
|
38.3%
|
22.7%
|
|
|
|
|
Imfinzi +
tremelimumab
(n=163)
|
Chemotherapy
(n=162)
|
OS (primary endpoint) in PD-L1 ≥25%a
|
|
|
Number
(%) of patients with event
|
113
(69.3%)
|
128
(79.0%)
|
HR
(98.77% CI)b,c
|
0.85
(0.611, 1.173)
|
|
p-valueb,d
|
0.202
|
|
Median
in months (95% CI)
|
11.9
(9.0, 17.7)
|
12.9
(10.5, 15.0)
|
24-month
OS rate
|
35.4%
|
22.7%
|
PFS (primary endpoint) in PD-L1 ≥25%i
|
|
|
Number
(%) of patients with event
|
118
(72.4%)
|
112
(69.1%)
|
HR
(99.5% CI)b,c
|
1.05
(0.722, 1.534)
|
|
p-value
|
0.705
|
|
Median
in months (95% CI)
|
3.9
(2.8, 5.0)
|
5.4
(4.6, 5.8)
|
12-month
PFS rate
|
25.8%
|
14.3%
|
Name
|
Phase
|
Population
|
Design
|
Timelines
|
Status
|
AEGEAN
|
III
|
Neo-adjuvant
(before surgery) NSCLC
|
SoC
chemotherapy +/- Imfinzi followed by
surgery
followed by placebo orImfinzi
|
FPCD[39] Q1
2019
First
data anticipated 2020
|
Recruitment
ongoing
|
ADJUVANT BR.31[40]
|
III
|
Stage
Ib-IIIa NSCLC
|
placebo
or
Imfinzi
|
FPCD Q1
2015
First
data anticipated 2020+
|
Recruitment
ongoing
|
PACIFIC
|
III
|
Unresectable,
Stage III NSCLC
|
concurrent CRT[41]
followed by
placebo
or
Imfinzi
|
FPCD Q2
2014
LPCD Q2
2016
|
PFS and
OS primary endpoints both met
|
PACIFIC-2
|
III
|
Unresectable,
Stage III NSCLC
|
concurrent
CRT concurrent with placebo or
Imfinzi followed
by
placebo or
Imfinzi
|
FPCD Q2
2018
First
data anticipated 2020+
|
Recruitment
ongoing
|
PACIFIC-4
|
III
|
Unresectable,
Stage I-II NSCLC
|
stereotactic
body
radiation therapy
followed by placebo
or
Imfinzi
|
FPCD Q1
2019
First
data anticipated 2020+
|
Recruitment
initiating
|
PACIFIC-5
|
III
|
Unresectable,
Stage III NSCLC
(Asia
predominant)
|
sequential
or concurrent
CRT followed by
placebo
or
Imfinzi
|
FPCD Q1
2019
First
data anticipated 2020+
|
Recruitment
ongoing
|
ADRIATIC
|
III
|
Limited-disease
stage small cell lung cancer (SCLC)
|
concurrent
CRT followed by
placebo
or Imfinzi or Imfinzi + treme
|
FPCD
Q4
2018
First
data anticipated 2020+
|
Recruitment
ongoing
|
PEARL
|
III
|
Stage
IV, 1st-line NSCLC (Asia)
|
SoC
chemotherapy or Imfinzi
|
FPCD
Q1
2017
First
data anticipated 2020
|
Recruitment
ongoing
|
MYSTIC
|
III
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or Imfinzi or Imfinzi + treme
|
FPCD
Q3
2015
LPCD
Q3
2016
|
Recruitment
completed
PFS and
OS primary endpoints not met
|
NEPTUNE
|
III
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or Imfinzi + treme
|
FPCD
Q4
2015
LPCD
Q2
2017
First
data anticipated H2 2019
|
Recruitment
completed
|
POSEIDON
|
III
|
Stage
IV, 1st-line NSCLC
|
SoC
chemotherapy or SoC + Imfinzior SoC + Imfinzi + treme
|
FPCD
Q2
2017
LPCD
Q3
2018
First
data anticipated H2 2019
|
Recruitment
completed
|
CASPIAN
|
III
|
Extensive-disease
stage SCLC
|
SoC
chemotherapy or SoC + Imfinzior SoC + Imfinzi + treme
|
FPCD Q1
2017
LPCD Q2
2018
First
data anticipated H2 2019
|
Recruitment
completed
|
Name
|
Phase
|
Population
|
Design
|
Timelines
|
Status
|
Stage I, II & III (non-metastatic disease)
|
|||||
POTOMAC
|
III
|
Non-muscle
invasive bladder cancer
|
SoC BCG or SoC BCG[42] + Imfinzi
|
FPCD
Q3
2018
First
data
anticipated
2020+
|
Recruitment
ongoing
|
NIAGARA
|
III
|
Muscle-invasive
bladder cancer
|
SoC
chemotherapy or SoC + Imfinzi
|
FPCD
Q12019
First
data
anticipated
2020+
|
Recruitment
ongoing
|
EMERALD-1
|
III
|
Locoregional
hepatocellular carcinoma (liver cancer)
|
transarterial
chemoembolisation (TACE) followed by placebo or TACE +Imfinzi followed byImfinzi + bevacizumab
or TACE
+ Imfinzi
followed
by Imfinzi
|
FPCD
Q1
2019
First
data
anticipated
2020+
|
Recruitment
ongoing
|
Stage IV (metastatic disease)
|
|||||
DANUBE
|
III
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible/ineligible bladder
cancer
|
SoC
chemotherapy or Imfinzi or Imfinzi+ treme
|
FPCD
Q4
2015
LPCD Q1
2017
First
data
anticipated
H2 2019
|
Recruitment
completed
|
NILE
|
III
|
Stage
IV, 1st-line cisplatin chemotherapy- eligible bladder
cancer
|
SoC
chemotherapy or SoC + Imfinzi or SoC + Imfinzi + treme
|
FPCD
Q3
2018
First
data
anticipated
2020+
|
Recruitmentongoing
|
KESTREL
|
III
|
Stage
IV, 1st-line HNSCC
|
SoC
or Imfinzi orImfinzi + treme
|
FPCD
Q4
2015
LPCD
Q1
2017
First
data
anticipated
H1 2019
|
Recruitment
completed
|
EAGLE
|
III
|
Stage
IV, 2nd-line HNSCC
|
SoC
or Imfinzi orImfinzi + treme
|
FPCD
Q4
2015
LPCD
Q3
2017
|
Recruitment
completed
OS
primary endpoints not met
|
HIMALAYA
|
III
|
Stage
IV, 1st-line unresectable hepatocellular carcinoma
|
sorafenib
or Imfinzior Imfinzi + treme
|
FPCD
Q4
2017
First
data
anticipated
2020+
|
Recruitment
ongoing
|
Name
|
Phase
|
Population
|
Design
|
Timelines
|
Status
|
PAOLA-1[43]
|
III
|
Stage
IV, 1st-line ovarian
cancer
|
bevacizumab
maintenance or bevacizumab
+ Lynparzamaintenance
|
FPCD
Q2
2015
LPCD
Q2
2018
First
data
anticipated
H2 2019
|
Recruitment
completed
|
DuO-O
|
III
|
Stage
IV, 1st-line ovarian
cancer
|
chemotherapy
+ bevacizumab
or chemotherapy
+ bevacizumab
+
Imfinzi +/- Lynparzamaintenance
|
FPCD Q1
2018
First
data
anticipated
2020+
|
Recruitmentongoing
|
GY005[44]
|
II/III
|
Platinum
resistant/refractory ovarian cancer
|
SoC
chemotherapy or cediranib orLynparza + cediranib
|
FPCD Q2
2016
First
data
anticipated
2020+
|
Recruitment
ongoing
|
MEDIOLA
|
I/II
|
Advanced,
2nd-line
gBRCAm
ovarian
cancer
Stage
IV, 1st to 3rd-line
gBRCAm, HER2-
negative
breast cancer
Stage
IV, 2nd-line SCLC
Stage
IV, 2nd-line
gastric
cancer
|
Lynparza + Imfinzi
|
FPCD
Q2
2016
|
Recruitmentongoing
Initial
data from lung, breast, prostate and ovarian-cancer cohorts
presented in 2017 and 2018
|
VIOLETTE
|
II
|
Stage
IV, advanced, triple-negative breast cancer:
-HRRm[45](BRCA)
-HRRm
(non-BRCA)
-Non-HRRm
|
Lynparza
Lynparza + ATR
(AZD6738)
Lynparza + WEE1
(AZD1775)
|
FPCD
Q2
2018
First
data anticipated
2020+
|
Recruitmentongoing
|
PROpel
|
III
|
Stage
IV, advanced, castration-resistant prostate cancer
|
abiraterone
or abiraterone
+
Lynparza
|
FPCD
Q4
2018
|
Recruitment
ongoing
|
BAYOU
|
II
|
Stage
IV, 1st line cis-platinum chemotherapy-ineligible
urothelial
bladder
cancer
|
Imfinzi or Imfinzi + Lynparza
|
FPCD
Q1
2018
First
data anticipated
2020
|
Recruitment
ongoing
|
DuO-LORION
|
II
|
Stage
IV, 1st-line
NSCLC
|
SoC
chemotherapy +Imfinzi followed byImfinzi or Imfinzi +Lynparza
maintenance
|
FPCD
Q4
2018
Data
anticipated 2020+
|
Recruitment
ongoing
|
Name
|
Phase
|
Population
|
Design
|
Timelines
|
Status
|
ACE-CL-007
ELEVATE-TN
|
III
|
Previously-untreated
CLL
|
chlorambucil
+ obinutuzumab
or
obinutuzumab +Calquence
or Calquence
|
FPCD
Q2
2015
Data
anticipated H2 2019
|
Recruitment
completed
|
ACE
CL-311
|
III
|
Previously-untreated
CLL
|
fludarabine,
cyclophosphamide and rituximab or Calquence + venetoclax
+/-
obinutuzumab
|
Data
anticipated 2020+
|
Initiating
|
ACE-CL-309
|
III
|
Relapsed/refractory
CLL
|
bendamustine
or idelalisib + rituximabor Calquence
|
FPCD
Q3
2016
Data
anticipated H2 2019
|
Recruitment
completed
|
ACE-CL-006
ELEVATE-RR
|
III
|
Relapsed/refractory
high risk CLL
|
ibrutinib
or Calquence
|
FPCD
Q2
2015
Data
anticipated 2020+
|
Recruitment
ongoing
|
Efficacy measure
|
Result (n=124; 95% CI)
|
ORRa
(complete response + partial response)
|
81% (73, 87)
|
Best response
|
|
Complete response
|
43% (34, 52)
|
Partial response
|
38% (29, 47)
|
Median duration of response
|
26 months (17.5, not reached)
|
Median PFS
|
20 months (16.5, 27.7)
|
Efficacy measure
|
Result (n=99)
|
ORRa (complete
response + partial response)
|
97%
|
Complete response
|
5%
|
Partial response
|
92%
|
Median duration of responseb
|
NR (range, 42.4 to NR)c
|
36-month duration of response rate (95% CI)b,d
|
98% (90, 99)
|
Median PFS
|
NR (range, 44.2 to NR)c
|
36-month PFS rate (95% CI)d
|
97% (91, 99)
|
Medicine
|
Trial
|
Mechanism
|
Population
|
Primary endpoint(s)
|
Timeline
|
Farxiga
|
DECLARE
|
SGLT2
inhibitor
|
c.17,000[46]patients
with type-2 diabetes
|
Superiority for MACE[47] or
superiority for the composite endpoint of CV death or
hHF
|
Primary
safety endpoint met
One of
two primary efficacy endpoints met
|
Farxiga
|
DAPA-HF
|
SGLT2
inhibitor
|
c.4,500
patients with heart failure (HF) and reduced ejection
fraction
|
Time to
first occurrence of CV death or hHF or an urgent HF
visit
|
FPCD Q1
2017
LPCDQ3
2018
Data
anticipated 2020
|
Farxiga
|
DELIVER
|
SGLT2
inhibitor
|
c.4,700
patients with HF and preserved ejection fraction
|
Time to
first occurrence of CV death or worsening heart
failure
|
FPCD Q3
2018
Data
anticipated 2020+
|
Farxiga
|
DAPA-CKD
|
SGLT2
inhibitor
|
c.4,000
patients with CKD
|
Time to first occurrence of ≥ 50% sustained decline in
eGFR[48] or
reaching ESRD[49] or
CV death or renal death
|
FPCD Q1
2017Data anticipated 2020
|
Brilinta
|
THEMIS
|
P2Y12
receptor antagonist
|
c.19,000
patients with type-2 diabetes and CAD without a history of MI or
stroke
|
Composite
of CV death, non-fatal MI and non-fatal stroke
|
FPCD Q1
2014
LPCD Q2
2016
Data
anticipated H1 2019
|
Brilinta
|
THALES
|
P2Y12
receptor antagonist
|
c.13,000
patients with acute ischaemic stroke or transient ischaemic
attack
|
Prevention
of the composite of subsequent stroke and death at 30
days
|
FPCD Q1
2018
Data
anticipated 2020
|
Epanova
|
STRENGTH
|
Omega-3
carboxylic acids
|
c.13,000
patients with mixed dyslipidaemia/
hypertriglycerid-aemia
|
Time to
first occurrence of CV death, non-fatal MI or non-fatal
stroke
|
FPCD Q4
2014
LPCD Q2
2017
Data
anticipated 2020
|
For
the year ended 31
December
|
|
2018
$m
|
|
2017
$m
|
Product
Sales
|
|
21,049
|
|
20,152
|
Externalisation
Revenue
|
|
1,041
|
|
2,313
|
Total Revenue
|
|
22,090
|
|
22,465
|
Cost of
sales
|
|
(4,936)
|
|
(4,318)
|
Gross profit
|
|
17,154
|
|
18,147
|
Distribution
costs
|
|
(331)
|
|
(310)
|
Research
and development expense
|
|
(5,932)
|
|
(5,757)
|
Selling,
general and administrative costs
|
|
(10,031)
|
|
(10,233)
|
Other
operating income and expense
|
|
2,527
|
|
1,830
|
Operating profit
|
|
3,387
|
|
3,677
|
Finance
income
|
|
138
|
|
113
|
Finance
expense
|
|
(1,419)
|
|
(1,508)
|
Share
of after tax losses in associates and joint ventures
|
|
(113)
|
|
(55)
|
Profit before tax
|
|
1,993
|
|
2,227
|
Taxation
|
|
57
|
|
641
|
Profit for the period
|
|
2,050
|
|
2,868
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
(46)
|
|
(242)
|
Net
losses on equity investments measured at fair value through other
comprehensive income
|
|
(171)
|
|
-
|
Fair
value movements related to own credit risk on bonds designated as
fair value through profit or loss
|
|
8
|
|
(9)
|
Tax on
items that will not be reclassified to profit or loss
|
|
56
|
|
16
|
|
|
(153)
|
|
(235)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
(450)
|
|
536
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
(520)
|
|
505
|
Fair
value movements on cash flow hedges
|
|
(37)
|
|
311
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
111
|
|
(315)
|
Fair
value movements on derivatives designated in net investment
hedges
Costs
of hedging
|
|
(8)
(54)
|
|
(48)
-
|
Amortisation
of loss on cash flow hedge
|
|
1
|
|
1
|
Net
available for sale losses taken to equity
|
|
-
|
|
(83)
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
51
|
|
(33)
|
|
|
(906)
|
|
874
|
Other comprehensive (loss)/income for the period, net of
tax
|
|
(1,059)
|
|
639
|
Total comprehensive income for the period
|
|
991
|
|
3,507
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
2,155
|
|
3,001
|
Non-controlling
interests
|
|
(105)
|
|
(133)
|
|
|
2,050
|
|
2,868
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,097
|
|
3,640
|
Non-controlling
interests
|
|
(106)
|
|
(133)
|
|
|
991
|
|
3,507
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$1.70
|
|
$2.37
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$1.70
|
|
$2.37
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,267
|
|
1,266
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,267
|
|
1,267
|
For
the quarter ended
31 December
|
|
2018
$m
|
|
2017
$m
|
Product
Sales
|
|
5,768
|
|
5,487
|
Externalisation
Revenue
|
|
649
|
|
290
|
Total Revenue
|
|
6,417
|
|
5,777
|
Cost of
sales
|
|
(1,637)
|
|
(1,225)
|
Gross profit
|
|
4,780
|
|
4,552
|
Distribution
costs
|
|
(93)
|
|
(85)
|
Research
and development expense
|
|
(2,012)
|
|
(1,551)
|
Selling,
general and administrative costs
|
|
(2,600)
|
|
(3,078)
|
Other
operating income and expense
|
|
1,002
|
|
848
|
Operating profit
|
|
1,077
|
|
686
|
Finance
income
|
|
26
|
|
49
|
Finance
expense
|
|
(337)
|
|
(316)
|
Share
of after tax losses in associates and joint ventures
|
|
(36)
|
|
(12)
|
Profit before tax
|
|
730
|
|
407
|
Taxation
|
|
279
|
|
854
|
Profit for the period
|
|
1,009
|
|
1,261
|
|
|
|
|
|
Other comprehensive income
|
|
|
|
|
Items that will not be reclassified to profit or loss
|
|
|
|
|
Remeasurement
of the defined benefit pension liability
|
|
(184)
|
|
(96)
|
Net
losses on equity investments measured at fair value through other
comprehensive income
|
|
(330)
|
|
-
|
Fair
value movements related to own credit risk on bonds designated as
fair value through profit or loss
|
|
5
|
|
(9)
|
Tax on
items that will not be reclassified to profit or loss
|
|
121
|
|
(7)
|
|
|
(388)
|
|
(112)
|
Items that may be reclassified subsequently to profit or
loss
|
|
|
|
|
Foreign
exchange arising on consolidation
|
|
(99)
|
|
5
|
Foreign
exchange arising on designating borrowings in net investment
hedges
|
|
(71)
|
|
(117)
|
Fair
value movements on cash flow hedges
|
|
(42)
|
|
85
|
Fair
value movements on cash flow hedges transferred to profit or
loss
|
|
39
|
|
(34)
|
Fair
value movements on derivatives designated in net investment
hedges
Costs
of hedging
|
|
(14)
(19)
|
|
(9)
-
|
Amortisation
of loss on cash flow hedge
|
|
1
|
|
-
|
Net
available for sale losses taken to equity
|
|
-
|
|
(47)
|
Tax on
items that may be reclassified subsequently to profit or
loss
|
|
12
|
|
92
|
|
|
(193)
|
|
(25)
|
Other comprehensive loss for the period, net of tax
|
|
(581)
|
|
(137)
|
Total comprehensive income for the period
|
|
428
|
|
1,124
|
|
|
|
|
|
Profit attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
1,034
|
|
1,301
|
Non-controlling
interests
|
|
(25)
|
|
(40)
|
|
|
1,009
|
|
1,261
|
|
|
|
|
|
Total comprehensive income attributable to:
|
|
|
|
|
Owners
of the Parent
|
|
453
|
|
1,164
|
Non-controlling
interests
|
|
(25)
|
|
(40)
|
|
|
428
|
|
1,124
|
|
|
|
|
|
Basic
earnings per $0.25 Ordinary Share
|
|
$0.82
|
|
$1.03
|
Diluted
earnings per $0.25 Ordinary Share
|
|
$0.82
|
|
$1.03
|
Weighted
average number of Ordinary Shares in issue (millions)
|
|
1,267
|
|
1,266
|
Diluted
weighted average number of Ordinary Shares in issue
(millions)
|
|
1,267
|
|
1,267
|
|
|
|
At 31 Dec
2018
$m
|
|
At 31 Dec
2017
$m
|
ASSETS
Non-current assets
|
|
|
|
|
|
Property,
plant and equipment
|
|
|
7,421
|
|
7,615
|
Goodwill
|
|
|
11,707
|
|
11,825
|
Intangible
assets
|
|
|
21,959
|
|
26,188
|
Derivative
financial instruments
|
|
|
157
|
|
504
|
Investments
in associates and joint ventures
|
|
|
89
|
|
103
|
Other
investments
|
|
|
833
|
|
933
|
Other
receivables
|
|
|
515
|
|
847
|
Deferred
tax assets
|
|
|
2,379
|
|
2,189
|
|
|
|
45,060
|
|
50,204
|
Current assets
|
|
|
|
|
|
Inventories
|
|
|
2,890
|
|
3,035
|
Trade
and other receivables
|
|
|
5,574
|
|
5,009
|
Other
investments
|
|
|
849
|
|
1,230
|
Derivative
financial instruments
|
|
|
258
|
|
28
|
Income
tax receivable
|
|
|
207
|
|
524
|
Cash
and cash equivalents
|
|
|
4,831
|
|
3,324
|
Assets
held for sale
|
|
|
982
|
-
|
-
|
|
|
|
15,591
|
|
13,150
|
Total assets
|
|
|
60,651
|
|
63,354
|
LIABILITIES
Current liabilities
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
|
(1,754)
|
|
(2,247)
|
Trade
and other payables
|
|
|
(12,841)
|
|
(11,641)
|
Derivative
financial instruments
|
|
|
(27)
|
|
(24)
|
Provisions
|
|
|
(506)
|
|
(1,121)
|
Income
tax payable
|
|
|
(1,164)
|
|
(1,350)
|
|
|
|
(16,292)
|
|
(16,383)
|
Non-current liabilities
|
|
|
|
|
|
Interest-bearing
loans and borrowings
|
|
|
(17,359)
|
|
(15,560)
|
Derivative
financial instruments
|
|
|
(4)
|
|
(4)
|
Deferred
tax liabilities
|
|
|
(3,286)
|
|
(3,995)
|
Retirement
benefit obligations
|
|
|
(2,511)
|
|
(2,583)
|
Provisions
|
|
|
(385)
|
|
(347)
|
Other
payables
|
|
|
(6,770)
|
|
(7,840)
|
|
|
|
(30,315)
|
|
(30,329)
|
Total liabilities
|
|
|
(46,607)
|
|
(46,712)
|
Net assets
|
|
|
14,044
|
|
16,642
|
EQUITY
|
|
|
|
|
|
Capital and reserves attributable to equity holders of the
Company
|
|
|
|
|
|
Share
capital
|
|
|
317
|
|
317
|
Share
premium account
|
|
|
4,427
|
|
4,393
|
Other
reserves
|
|
|
2,041
|
|
2,029
|
Retained
earnings
|
|
|
5,683
|
|
8,221
|
|
|
|
12,468
|
|
14,960
|
Non-controlling interests
|
|
|
1,576
|
|
1,682
|
Total equity
|
|
|
14,044
|
|
16,642
|
|
|
Share
capital
$m
|
|
Share premium account
$m
|
|
Other reserves[50]
$m
|
|
Retained
earnings
$m
|
|
Total
attributable
to
owners
$m
|
|
Non-
controlling interests
$m
|
|
Total
equity
$m
|
|
At
1 Jan 2017
|
|
316
|
|
4,351
|
|
2,047
|
|
8,140
|
|
14,854
|
|
1,815
|
|
16,669
|
|
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
3,001
|
|
3,001
|
|
(133)
|
|
2,868
|
|
Other
comprehensive income
|
|
-
|
|
-
|
|
-
|
|
639
|
|
639
|
|
-
|
|
639
|
|
Transfer to other
reserves
|
|
-
|
|
-
|
|
(18)
|
|
18
|
|
-
|
|
-
|
|
-
|
|
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
|
-
|
|
-
|
|
(3,543)
|
|
(3,543)
|
|
-
|
|
(3,543)
|
|
Issue
of Ordinary Shares
|
|
1
|
|
42
|
|
-
|
|
-
|
|
43
|
|
-
|
|
43
|
|
Share-based
payments charge for the period
|
|
-
|
|
-
|
|
-
|
|
220
|
|
220
|
|
-
|
|
220
|
|
Settlement of share
plan awards
|
|
-
|
|
-
|
|
-
|
|
(254)
|
|
(254)
|
|
-
|
|
(254)
|
|
Net
movement
|
|
1
|
|
42
|
|
(18)
|
|
81
|
|
106
|
|
(133)
|
|
(27)
|
|
At
31 Dec 2017
|
|
317
|
|
4,393
|
|
2,029
|
|
8,221
|
|
14,960
|
|
1,682
|
|
16,642
|
|
|
|
Share
capital
$m
|
|
Share premium
account
$m
|
|
Otherreserves$m
|
|
Retainedearnings$m
|
|
Total
attributable
to
owners
$m
|
|
Non-
controlling interests
$m
|
|
Totalequity$m
|
|
At
1 Jan 2018
|
|
317
|
|
4,393
|
|
2,029
|
|
8,221
|
|
14,960
|
|
1,682
|
|
16,642
|
|
Adoption of new accounting
standards[51]
|
|
-
|
-
|
-
|
-
|
-
|
|
(91)
|
|
(91)
|
|
-
|
|
(91)
|
|
Profit
for the period
|
|
-
|
|
-
|
|
-
|
|
2,155
|
|
2,155
|
|
(105)
|
|
2,050
|
|
Other
comprehensive loss
|
|
-
|
|
-
|
|
-
|
|
(1,058)
|
|
(1,058)
|
|
(1)
|
|
(1,059)
|
|
Transfer to other
reserves
|
|
-
|
|
-
|
|
12
|
|
(12)
|
|
-
|
|
-
|
|
-
|
|
Transactions
with owners:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends
|
|
-
|
|
-
|
|
-
|
|
(3,539)
|
|
(3,539)
|
|
-
|
|
(3,539)
|
|
Issue
of Ordinary Shares
|
|
-
|
|
34
|
|
-
|
|
-
|
|
34
|
|
-
|
|
34
|
|
Share-based
payments charge for the period
|
|
-
|
|
-
|
|
-
|
|
219
|
|
219
|
|
-
|
|
219
|
|
Settlement of share
plan awards
|
|
-
|
|
-
|
|
-
|
|
(212)
|
|
(212)
|
|
-
|
|
(212)
|
|
Net
movement
|
|
-
|
|
34
|
|
12
|
|
(2,538)
|
|
(2,492)
|
|
(106)
|
|
(2,598)
|
|
At
31 Dec 2018
|
|
317
|
|
4,427
|
|
2,041
|
|
5,683
|
|
12,468
|
|
1,576
|
|
14,044
|
For
the year ended 31
December
|
|
2018
$m
|
|
2017
$m
|
Cash flows from operating activities
|
|
|
|
|
Profit
before tax
|
|
1,993
|
|
2,227
|
Finance
income and expense
|
|
1,281
|
|
1,395
|
Share
of after tax losses in associates and joint ventures
|
|
113
|
|
55
|
Depreciation,
amortisation and impairment
|
|
3,753
|
|
3,036
|
Increase
in working capital and short-term provisions
|
|
(639)
|
|
(50)
|
Gains
on disposal of intangible assets
|
|
(1,885)
|
|
(1,518)
|
Fair
value movements on contingent consideration arising from business
combinations
|
|
(495)
|
|
109
|
Non-cash
and other movements
|
|
(290)
|
|
(524)
|
Cash generated from operations
|
|
3,831
|
|
4,730
|
Interest
paid
|
|
(676)
|
|
(698)
|
Tax
paid
|
|
(537)
|
|
(454)
|
Net cash inflow from operating activities
|
|
2,618
|
|
3,578
|
Cash flows from investing activities
|
|
|
|
|
Movement
in short-term investments and fixed deposits
|
|
405
|
|
(345)
|
Purchase
of property, plant and equipment
|
|
(1,043)
|
|
(1,326)
|
Disposal
of property, plant and equipment
|
|
12
|
|
83
|
Purchase
of intangible assets
|
|
(328)
|
|
(294)
|
Disposal
of intangible assets
|
|
2,338
|
|
1,376
|
Purchase
of non-current asset investments
|
|
(102)
|
|
(96)
|
Disposal
of non-current asset investments
|
|
24
|
|
70
|
Payments
to joint ventures
|
|
(187)
|
|
(76)
|
Non-contingent
payments on business combinations
|
|
-
|
|
(1,450)
|
Payment
of contingent consideration from business combinations
|
|
(349)
|
|
(434)
|
Interest
received
|
|
193
|
|
164
|
Net cash inflow/(outflow) from investing activities
|
|
963
|
|
(2,328)
|
Net cash inflow before financing activities
|
|
3,581
|
|
1,250
|
Cash flows from financing activities
|
|
|
|
|
Proceeds
from issue of share capital
|
|
34
|
|
43
|
Issue
of loans
|
|
2,971
|
|
1,988
|
Repayment
of loans
|
|
(1,400)
|
|
(1,750)
|
Dividends
paid
|
|
(3,484)
|
|
(3,519)
|
Hedge
contracts relating to dividend payments
|
|
(67)
|
|
(20)
|
Repayment
of obligations under finance leases
|
|
-
|
|
(14)
|
Movement
in short-term borrowings
|
|
(98)
|
|
336
|
Net cash outflow from financing activities
|
|
(2,044)
|
|
(2,936)
|
Net
increase/(decrease) in cash and cash equivalents in the
period
|
|
1,537
|
|
(1,686)
|
Cash
and cash equivalents at the beginning of the period
|
|
3,172
|
|
4,924
|
Exchange
rate effects
|
|
(38)
|
|
(66)
|
Cash and cash equivalents at the end of the period
|
|
4,671
|
|
3,172
|
Cash and cash equivalents consist of:
|
|
|
|
|
Cash
and cash equivalents
|
|
4,831
|
|
3,324
|
Overdrafts
|
|
(160)
|
|
(152)
|
|
|
4,671
|
|
3,172
|
|
|
FY
2018$m
|
|
FY
2017$m
|
|
Q4
2018
$m
|
|
Q4
2017
$m
|
Cost of
sales
|
|
432
|
|
181
|
|
355
|
|
53
|
Research and
development expense
|
|
94
|
|
201
|
|
(1)
|
|
24
|
Selling, general
and administrative costs
|
|
181
|
|
347
|
|
71
|
|
83
|
Other
operating income and expense
|
|
(10)
|
|
78
|
|
1
|
|
3
|
Total
|
|
697
|
|
807
|
|
426
|
|
163
|
|
|
At 1 Jan
2018
$m
|
|
Cash
Flow
$m
|
|
Non-cash
&
Other
$m
|
|
Exchange
Movements
$m
|
|
At
31 Dec
2018
$m
|
Loans
due after one year
|
|
(15,560)
|
|
(2,971)
|
|
1,006
|
|
166
|
|
(17,359)
|
Total
long-term debt
|
|
(15,560)
|
|
(2,971)
|
|
1,006
|
|
166
|
|
(17,359)
|
|
|
|
|
|
|
|
|
|
|
|
Current
instalments of loans
|
|
(1,397)
|
|
1,400
|
|
(1,002)
|
|
-
|
|
(999)
|
Current
instalments of finance leases
|
|
(5)
|
|
-
|
|
5
|
|
-
|
|
-
|
Commercial
paper
|
|
(180)
|
|
(31)
|
|
-
|
|
-
|
|
(211)
|
Bank
Collateral
|
|
(513)
|
|
129
|
|
-
|
|
-
|
|
(384)
|
Overdraft
|
|
(152)
|
|
(19)
|
|
-
|
|
11
|
|
(160)
|
Total
current debt
|
|
(2,247)
|
|
1,479
|
|
(997)
|
|
11
|
|
(1,754)
|
|
|
|
|
|
|
|
|
|
|
|
Gross
borrowings
|
|
(17,807)
|
|
(1,492)
|
|
9
|
|
177
|
|
(19,113)
|
|
|
|
|
|
|
|
|
|
|
|
Net
derivative financial instruments
|
|
504
|
|
67
|
|
(187)
|
|
-
|
|
384
|
|
|
|
|
|
|
|
|
|
|
|
Net
Borrowings
|
|
(17,303)
|
|
(1,425)
|
|
(178)
|
|
177
|
|
(18,729)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
and cash equivalents
|
|
3,324
|
|
1,556
|
|
-
|
|
(49)
|
|
4,831
|
Other
investments - current
|
|
1,230
|
|
(405)
|
|
24
|
|
-
|
|
849
|
Other
investments - non-current
|
|
70
|
|
-
|
|
(24)
|
|
-
|
|
46
|
Cash
and investments
|
|
4,624
|
|
1,151
|
|
-
|
|
(49)
|
|
5,726
|
|
|
|
|
|
|
|
|
|
|
|
Net
funds / (debt)
|
|
(12,679)
|
|
(274)
|
|
(178)
|
|
128
|
|
(13,003)
|
|
|
Diabetes
Alliance
2018
|
|
Other
2018
|
|
Total
2018
|
|
Total
2017
|
|
|
$m
|
|
$m
|
|
$m
|
|
$m
|
At
1 January
|
|
4,477
|
|
1,057
|
|
5,534
|
|
5,457
|
Settlements
|
|
(349)
|
|
-
|
|
(349)
|
|
(434)
|
Revaluations
|
|
(482)
|
|
(13)
|
|
(495)
|
|
109
|
Discount
unwind
|
|
337
|
|
79
|
|
416
|
|
402
|
At
31 December
|
|
3,983
|
|
1,123
|
|
5,106
|
|
5,534
|
|
World
|
|
Emerging Markets
|
|
US
|
|
Europe
|
|
Established ROW
|
||||||||||||||
|
FY 2018
$m
|
|
Actual
%
|
CER
%
|
|
FY 2018
$m
|
|
Actual
%
|
CER %
|
|
FY 2018
$m
|
|
Actual
%
|
|
FY 2018
$m
|
|
Actual
%
|
CER
%
|
|
FY 2018
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
1,860
|
|
95
|
93
|
|
347
|
|
n/m
|
n/m
|
|
869
|
|
n/m
|
|
314
|
|
68
|
61
|
|
330
|
|
45
|
43
|
Lynparza
|
647
|
|
n/m
|
n/m
|
|
51
|
|
n/m
|
n/m
|
|
345
|
|
n/m
|
|
190
|
|
46
|
41
|
|
61
|
|
n/m
|
n/m
|
Imfinzi
|
633
|
|
n/m
|
n/m
|
|
6
|
|
n/m
|
n/m
|
|
564
|
|
n/m
|
|
27
|
|
n/m
|
n/m
|
|
36
|
|
n/m
|
n/m
|
Iressa
|
518
|
|
(2)
|
(4)
|
|
286
|
|
14
|
12
|
|
26
|
|
(33)
|
|
109
|
|
(3)
|
(8)
|
|
97
|
|
(23)
|
(25)
|
Calquence
|
62
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
62
|
|
n/m
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
1,028
|
|
9
|
9
|
|
154
|
|
34
|
41
|
|
537
|
|
9
|
|
221
|
|
(14)
|
(19)
|
|
116
|
|
49
|
46
|
Zoladex
|
752
|
|
2
|
2
|
|
409
|
|
16
|
18
|
|
8
|
|
(47)
|
|
133
|
|
(6)
|
(10)
|
|
202
|
|
(11)
|
(12)
|
Arimidex
|
212
|
|
(2)
|
(3)
|
|
132
|
|
12
|
11
|
|
-
|
|
n/m
|
|
31
|
|
(9)
|
(9)
|
|
49
|
|
(16)
|
(17)
|
Casodex
|
201
|
|
(7)
|
(8)
|
|
113
|
|
5
|
2
|
|
1
|
|
n/m
|
|
20
|
|
(9)
|
(9)
|
|
67
|
|
(22)
|
(23)
|
Others
|
115
|
|
1
|
(1)
|
|
30
|
|
29
|
30
|
|
-
|
|
-
|
|
8
|
|
20
|
20
|
|
77
|
|
(7)
|
(8)
|
Total Oncology
|
6,028
|
|
50
|
49
|
|
1,528
|
|
36
|
37
|
|
2,412
|
|
n/m
|
|
1,053
|
|
19
|
14
|
|
1,035
|
|
16
|
14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
1,391
|
|
30
|
30
|
|
336
|
|
45
|
52
|
|
591
|
|
21
|
|
315
|
|
30
|
24
|
|
149
|
|
34
|
34
|
Brilinta
|
1,321
|
|
22
|
21
|
|
326
|
|
46
|
48
|
|
588
|
|
16
|
|
348
|
|
18
|
13
|
|
59
|
|
16
|
16
|
Bydureon
|
584
|
|
2
|
1
|
|
8
|
|
(11)
|
(11)
|
|
475
|
|
4
|
|
81
|
|
(8)
|
(13)
|
|
20
|
|
5
|
5
|
Onglyza
|
543
|
|
(11)
|
(11)
|
|
172
|
|
32
|
34
|
|
223
|
|
(30)
|
|
89
|
|
(14)
|
(18)
|
|
59
|
|
4
|
4
|
Byetta
|
126
|
|
(28)
|
(28)
|
|
8
|
|
(33)
|
(33)
|
|
74
|
|
(35)
|
|
29
|
|
(15)
|
(15)
|
|
15
|
|
(6)
|
(6)
|
Symlin
|
34
|
|
(29)
|
(29)
|
|
-
|
|
-
|
-
|
|
34
|
|
(29)
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
1,433
|
|
(39)
|
(40)
|
|
841
|
|
7
|
7
|
|
170
|
|
(54)
|
|
203
|
|
(70)
|
(71)
|
|
219
|
|
(60)
|
(60)
|
Seloken/Toprol-XL
|
712
|
|
2
|
4
|
|
641
|
|
8
|
10
|
|
39
|
|
5
|
|
19
|
|
(63)
|
(63)
|
|
13
|
|
-
|
-
|
Atacand
|
260
|
|
(13)
|
(12)
|
|
157
|
|
(12)
|
(7)
|
|
13
|
|
(32)
|
|
70
|
|
(19)
|
(20)
|
|
20
|
|
18
|
18
|
Others
|
306
|
|
(11)
|
(12)
|
|
206
|
|
-
|
-
|
|
(1)
|
|
n/m
|
|
76
|
|
(17)
|
(20)
|
|
25
|
|
(42)
|
(42)
|
Total CVRM
|
6,710
|
|
(8)
|
(8)
|
|
2,695
|
|
14
|
15
|
|
2,206
|
|
(7)
|
|
1,230
|
|
(26)
|
(29)
|
|
579
|
|
(33)
|
(34)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
2,561
|
|
(9)
|
(10)
|
|
495
|
|
13
|
14
|
|
862
|
|
(22)
|
|
773
|
|
(6)
|
(10)
|
|
431
|
|
(3)
|
(4)
|
Pulmicort
|
1,286
|
|
9
|
8
|
|
995
|
|
18
|
17
|
|
116
|
|
(26)
|
|
90
|
|
(2)
|
(8)
|
|
85
|
|
(3)
|
(5)
|
Fasenra
|
297
|
|
n/m
|
n/m
|
|
1
|
|
n/m
|
n/m
|
|
218
|
|
n/m
|
|
32
|
|
n/m
|
n/m
|
|
46
|
|
n/m
|
n/m
|
Daliresp/Daxas
|
189
|
|
(5)
|
(5)
|
|
5
|
|
25
|
25
|
|
155
|
|
(7)
|
|
28
|
|
8
|
4
|
|
1
|
|
-
|
-
|
Tudorza/Eklira
|
110
|
|
(27)
|
(29)
|
|
1
|
|
(50)
|
n/m
|
|
25
|
|
(62)
|
|
74
|
|
1
|
(3)
|
|
10
|
|
11
|
11
|
Duaklir
|
95
|
|
20
|
14
|
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
|
91
|
|
18
|
12
|
|
3
|
|
50
|
50
|
Bevespi
|
33
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
33
|
|
n/m
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Others
|
340
|
|
20
|
18
|
|
146
|
|
42
|
41
|
|
7
|
|
40
|
|
141
|
|
9
|
6
|
|
46
|
|
(2)
|
(2)
|
Total Respiratory
|
4,911
|
|
4
|
3
|
|
1,644
|
|
18
|
18
|
|
1,416
|
|
(6)
|
|
1,229
|
|
1
|
(4)
|
|
622
|
|
5
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
1,702
|
|
(13)
|
(14)
|
|
690
|
|
1
|
1
|
|
306
|
|
(39)
|
|
235
|
|
(5)
|
(10)
|
|
471
|
|
(10)
|
(11)
|
Synagis
|
665
|
|
(3)
|
(3)
|
|
1
|
|
n/m
|
n/m
|
|
287
|
|
(9)
|
|
377
|
|
2
|
2
|
|
-
|
|
-
|
-
|
Seroquel XR/IR
|
361
|
|
(29)
|
(31)
|
|
118
|
|
(22)
|
(23)
|
|
108
|
|
(44)
|
|
107
|
|
(16)
|
(20)
|
|
28
|
|
(26)
|
(26)
|
Losec/Prilosec
|
272
|
|
-
|
(2)
|
|
161
|
|
15
|
11
|
|
7
|
|
(36)
|
|
70
|
|
(9)
|
(12)
|
|
34
|
|
(21)
|
(21)
|
FluMist/Fluenz
|
110
|
|
41
|
44
|
|
1
|
|
n/m
|
n/m
|
|
15
|
|
n/m
|
|
91
|
|
20
|
22
|
|
3
|
|
-
|
-
|
Movantik/Moventig
|
109
|
|
(11)
|
(11)
|
|
-
|
|
-
|
-
|
|
108
|
|
(10)
|
|
-
|
|
n/m
|
n/m
|
|
1
|
|
n/m
|
n/m
|
Others
|
181
|
|
(66)
|
(67)
|
|
53
|
|
(82)
|
(79)
|
|
11
|
|
(59)
|
|
67
|
|
(27)
|
(41)
|
|
50
|
|
(59)
|
(60)
|
Total Other
|
3,400
|
|
(18)
|
(19)
|
|
1,024
|
|
(19)
|
(19)
|
|
842
|
|
(28)
|
|
947
|
|
(5)
|
(8)
|
|
587
|
|
(19)
|
(20)
|
Total Product Sales
|
21,049
|
|
4
|
4
|
|
6,891
|
|
12
|
13
|
|
6,876
|
|
11
|
|
4,459
|
|
(6)
|
(10)
|
|
2,823
|
|
(8)
|
(9)
|
|
World
|
|
Emerging Markets
|
|
US
|
|
Europe
|
|
Established ROW
|
||||||||||||||
|
Q4 2018
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2018
$m
|
|
Actual
%
|
CER %
|
|
Q4 2018
$m
|
|
Actual
%
|
|
Q4 2018
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2018
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
594
|
|
95
|
98
|
|
81
|
|
62
|
78
|
|
289
|
|
n/m
|
|
92
|
|
46
|
48
|
|
132
|
|
n/m
|
n/m
|
Lynparza
|
209
|
|
n/m
|
n/m
|
|
18
|
|
n/m
|
n/m
|
|
112
|
|
n/m
|
|
53
|
|
47
|
50
|
|
26
|
|
n/m
|
n/m
|
Imfinzi
|
262
|
|
n/m
|
n/m
|
|
2
|
|
n/m
|
n/m
|
|
216
|
|
n/m
|
|
18
|
|
n/m
|
n/m
|
|
26
|
|
n/m
|
n/m
|
Iressa
|
112
|
|
(14)
|
(11)
|
|
60
|
|
18
|
24
|
|
6
|
|
(50)
|
|
24
|
|
(25)
|
(22)
|
|
22
|
|
(37)
|
(37)
|
Calquence
|
24
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
24
|
|
n/m
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
269
|
|
13
|
16
|
|
43
|
|
59
|
81
|
|
143
|
|
15
|
|
50
|
|
(19)
|
(19)
|
|
33
|
|
32
|
32
|
Zoladex
|
182
|
|
(3)
|
3
|
|
96
|
|
3
|
12
|
|
2
|
|
n/m
|
|
34
|
|
(8)
|
(5)
|
|
50
|
|
(14)
|
(12)
|
Arimidex
|
46
|
|
(19)
|
(16)
|
|
26
|
|
(21)
|
(18)
|
|
-
|
|
n/m
|
|
8
|
|
-
|
13
|
|
12
|
|
(14)
|
(14)
|
Casodex
|
46
|
|
(15)
|
(13)
|
|
23
|
|
(23)
|
(20)
|
|
-
|
|
n/m
|
|
5
|
|
-
|
-
|
|
18
|
|
(14)
|
(14)
|
Others
|
23
|
|
(21)
|
(17)
|
|
6
|
|
(14)
|
-
|
|
-
|
|
-
|
|
3
|
|
n/m
|
n/m
|
|
14
|
|
(39)
|
(39)
|
Total Oncology
|
1,767
|
|
58
|
61
|
|
355
|
|
19
|
30
|
|
792
|
|
134
|
|
287
|
|
19
|
21
|
|
333
|
|
38
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
397
|
|
20
|
24
|
|
94
|
|
31
|
42
|
|
171
|
|
14
|
|
84
|
|
18
|
24
|
|
48
|
|
23
|
28
|
Brilinta
|
376
|
|
26
|
29
|
|
94
|
|
92
|
n/m
|
|
177
|
|
15
|
|
91
|
|
11
|
13
|
|
14
|
|
-
|
-
|
Bydureon
|
138
|
|
(6)
|
(5)
|
|
(1)
|
|
n/m
|
n/m
|
|
115
|
|
-
|
|
19
|
|
(17)
|
(13)
|
|
5
|
|
-
|
-
|
Onglyza
|
148
|
|
(18)
|
(15)
|
|
51
|
|
38
|
49
|
|
61
|
|
(41)
|
|
21
|
|
(19)
|
(19)
|
|
15
|
|
7
|
14
|
Byetta
|
32
|
|
(33)
|
(31)
|
|
2
|
|
(33)
|
-
|
|
19
|
|
(42)
|
|
7
|
|
(13)
|
(13)
|
|
4
|
|
-
|
-
|
Symlin
|
10
|
|
(23)
|
(23)
|
|
-
|
|
-
|
-
|
|
10
|
|
(23)
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
353
|
|
(41)
|
(38)
|
|
210
|
|
1
|
7
|
|
42
|
|
(67)
|
|
44
|
|
(71)
|
(70)
|
|
57
|
|
(47)
|
(47)
|
Seloken/Toprol-XL
|
160
|
|
(5)
|
4
|
|
148
|
|
(5)
|
4
|
|
6
|
|
n/m
|
|
3
|
|
(25)
|
(25)
|
|
3
|
|
(40)
|
(40)
|
Atacand
|
58
|
|
(21)
|
(14)
|
|
43
|
|
-
|
12
|
|
2
|
|
-
|
|
8
|
|
(65)
|
(65)
|
|
5
|
|
-
|
-
|
Others
|
75
|
|
(12)
|
(8)
|
|
50
|
|
4
|
10
|
|
1
|
|
(50)
|
|
18
|
|
(22)
|
(22)
|
|
6
|
|
(50)
|
(50)
|
Total CVRM
|
1,747
|
|
(10)
|
(6)
|
|
691
|
|
12
|
21
|
|
604
|
|
(14)
|
|
295
|
|
(28)
|
(26)
|
|
157
|
|
(24)
|
(22)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
636
|
|
(15)
|
(13)
|
|
131
|
|
12
|
20
|
|
207
|
|
(28)
|
|
185
|
|
(19)
|
(17)
|
|
113
|
|
(4)
|
(2)
|
Pulmicort
|
389
|
|
5
|
9
|
|
307
|
|
14
|
20
|
|
35
|
|
(29)
|
|
22
|
|
(15)
|
(15)
|
|
25
|
|
(7)
|
(7)
|
Fasenra
|
125
|
|
n/m
|
n/m
|
|
1
|
|
n/m
|
n/m
|
|
89
|
|
n/m
|
|
15
|
|
n/m
|
n/m
|
|
20
|
|
n/m
|
n/m
|
Daliresp/Daxas
|
54
|
|
2
|
4
|
|
1
|
|
n/m
|
n/m
|
|
45
|
|
5
|
|
8
|
|
(20)
|
(20)
|
|
-
|
|
-
|
-
|
Tudorza/Eklira
|
19
|
|
(55)
|
(55)
|
|
-
|
|
n/m
|
n/m
|
|
(3)
|
|
n/m
|
|
20
|
|
11
|
11
|
|
2
|
|
(33)
|
(33)
|
Duaklir
|
22
|
|
(4)
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
|
21
|
|
(9)
|
(9)
|
|
1
|
|
n/m
|
n/m
|
Bevespi
|
10
|
|
25
|
25
|
|
-
|
|
-
|
-
|
|
10
|
|
25
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
Others
|
107
|
|
26
|
32
|
|
57
|
|
54
|
65
|
|
3
|
|
(25)
|
|
36
|
|
16
|
16
|
|
11
|
|
(27)
|
(20)
|
Total Respiratory
|
1,362
|
|
2
|
5
|
|
497
|
|
17
|
25
|
|
386
|
|
(6)
|
|
307
|
|
(9)
|
(7)
|
|
172
|
|
6
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
390
|
|
(9)
|
(6)
|
|
166
|
|
(1)
|
5
|
|
57
|
|
-
|
|
56
|
|
(22)
|
(22)
|
|
111
|
|
(15)
|
(14)
|
Synagis
|
251
|
|
7
|
7
|
|
1
|
|
n/m
|
n/m
|
|
154
|
|
14
|
|
96
|
|
(3)
|
(3)
|
|
-
|
|
-
|
-
|
FluMist/Fluenz
|
75
|
|
29
|
33
|
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
|
71
|
|
22
|
26
|
|
3
|
|
n/m
|
n/m
|
Losec/Prilosec
|
60
|
|
(13)
|
(9)
|
|
30
|
|
(17)
|
(14)
|
|
2
|
|
-
|
|
19
|
|
(5)
|
5
|
|
9
|
|
(18)
|
(18)
|
Seroquel XR/IR
|
56
|
|
(65)
|
(64)
|
|
12
|
|
(69)
|
(67)
|
|
13
|
|
(84)
|
|
26
|
|
(13)
|
(13)
|
|
5
|
|
(44)
|
(44)
|
Movantik/Moventig
|
25
|
|
(17)
|
(17)
|
|
-
|
|
-
|
-
|
|
27
|
|
(7)
|
|
(2)
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
Others
|
35
|
|
(70)
|
(68)
|
|
13
|
|
(73)
|
(88)
|
|
2
|
|
(86)
|
|
18
|
|
(18)
|
9
|
|
2
|
|
(94)
|
(84)
|
Total Other
|
892
|
|
(18)
|
(17)
|
|
223
|
|
(23)
|
(21)
|
|
255
|
|
(20)
|
|
284
|
|
(6)
|
(3)
|
|
130
|
|
(29)
|
(27)
|
Total Product Sales
|
5,768
|
|
5
|
8
|
|
1,766
|
|
8
|
16
|
|
2,037
|
|
15
|
|
1,173
|
|
(9)
|
(7)
|
|
792
|
|
-
|
1
|
|
Q1 2018
$m
|
|
Actual
%
|
CER
%
|
|
Q2 2018
$m
|
|
Actual
%
|
CER
%
|
|
Q3 2018
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2018
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
338
|
|
11
|
10
|
|
422
|
|
25
|
25
|
|
506
|
|
20
|
23
|
|
594
|
|
17
|
19
|
Iressa
|
132
|
|
2
|
(1)
|
|
143
|
|
8
|
8
|
|
131
|
|
(8)
|
(5)
|
|
112
|
|
(15)
|
(13)
|
Lynparza
|
119
|
|
19
|
18
|
|
150
|
|
26
|
26
|
|
169
|
|
13
|
15
|
|
209
|
|
24
|
25
|
Imfinzi
|
62
|
|
n/m
|
n/m
|
|
122
|
|
98
|
98
|
|
187
|
|
53
|
52
|
|
262
|
|
40
|
41
|
Calquence
|
8
|
|
n/m
|
n/m
|
|
12
|
|
51
|
50
|
|
18
|
|
50
|
50
|
|
24
|
|
33
|
33
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
254
|
|
7
|
5
|
|
247
|
|
(3)
|
(2)
|
|
258
|
|
4
|
7
|
|
269
|
|
4
|
5
|
Zoladex
|
184
|
|
(2)
|
(4)
|
|
192
|
|
4
|
5
|
|
194
|
|
1
|
6
|
|
182
|
|
(6)
|
(2)
|
Arimidex
|
54
|
|
(5)
|
(7)
|
|
57
|
|
6
|
6
|
|
55
|
|
(4)
|
-
|
|
46
|
|
(16)
|
(13)
|
Casodex
|
52
|
|
(4)
|
(6)
|
|
52
|
|
-
|
(2)
|
|
51
|
|
(2)
|
4
|
|
46
|
|
(10)
|
(8)
|
Others
|
27
|
|
(7)
|
(20)
|
|
37
|
|
37
|
50
|
|
28
|
|
(24)
|
(22)
|
|
23
|
|
(18)
|
13
|
Total Oncology
|
1,230
|
|
10
|
8
|
|
1,434
|
|
17
|
17
|
|
1,597
|
|
11
|
14
|
|
1,767
|
|
11
|
13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
299
|
|
(10)
|
(11)
|
|
340
|
|
14
|
15
|
|
355
|
|
4
|
7
|
|
397
|
|
12
|
13
|
Brilinta
|
293
|
|
(2)
|
(4)
|
|
316
|
|
8
|
9
|
|
336
|
|
6
|
9
|
|
376
|
|
12
|
13
|
Onglyza
|
129
|
|
(28)
|
(29)
|
|
126
|
|
(2)
|
(2)
|
|
140
|
|
11
|
14
|
|
148
|
|
6
|
8
|
Bydureon
|
139
|
|
(5)
|
(5)
|
|
155
|
|
12
|
11
|
|
152
|
|
(2)
|
(1)
|
|
138
|
|
(9)
|
(9)
|
Byetta
|
31
|
|
(35)
|
(38)
|
|
29
|
|
(7)
|
(3)
|
|
34
|
|
17
|
17
|
|
32
|
|
(6)
|
(6)
|
Symlin
|
9
|
|
(31)
|
(31)
|
|
7
|
|
(22)
|
(22)
|
|
8
|
|
14
|
14
|
|
10
|
|
25
|
25
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
389
|
|
(35)
|
(36)
|
|
338
|
|
(13)
|
(12)
|
|
353
|
|
4
|
8
|
|
353
|
|
-
|
2
|
Seloken/Toprol-XL
|
200
|
|
19
|
18
|
|
173
|
|
(14)
|
(13)
|
|
179
|
|
3
|
10
|
|
160
|
|
(11)
|
(8)
|
Atacand
|
71
|
|
(3)
|
(3)
|
|
66
|
|
(8)
|
(8)
|
|
65
|
|
(2)
|
5
|
|
58
|
|
(11)
|
(9)
|
Others
|
85
|
|
6
|
4
|
|
73
|
|
(13)
|
(11)
|
|
73
|
|
(3)
|
-
|
|
75
|
|
3
|
3
|
Total CVRM
|
1,645
|
|
(15)
|
(17)
|
|
1,623
|
|
(1)
|
-
|
|
1,695
|
|
4
|
8
|
|
1,747
|
|
3
|
5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
634
|
|
(16)
|
(17)
|
|
672
|
|
6
|
6
|
|
619
|
|
(8)
|
(5)
|
|
636
|
|
3
|
4
|
Pulmicort
|
346
|
|
(7)
|
(8)
|
|
287
|
|
(17)
|
(17)
|
|
264
|
|
(8)
|
(4)
|
|
389
|
|
47
|
51
|
Daliresp/Daxas
|
38
|
|
(28)
|
(30)
|
|
45
|
|
19
|
22
|
|
52
|
|
16
|
18
|
|
54
|
|
4
|
4
|
Tudorza/Eklira
|
34
|
|
(19)
|
(21)
|
|
39
|
|
15
|
15
|
|
18
|
|
(54)
|
(59)
|
|
19
|
|
6
|
11
|
Duaklir
|
28
|
|
22
|
17
|
|
22
|
|
(22)
|
(19)
|
|
23
|
|
5
|
5
|
|
22
|
|
(4)
|
-
|
Fasenra
|
21
|
|
n/m
|
n/m
|
|
65
|
|
n/m
|
n/m
|
|
86
|
|
32
|
34
|
|
125
|
|
45
|
46
|
Bevespi
|
5
|
|
(38)
|
(38)
|
|
8
|
|
61
|
60
|
|
10
|
|
25
|
25
|
|
10
|
|
-
|
-
|
Others
|
75
|
|
(12)
|
(20)
|
|
88
|
|
17
|
16
|
|
70
|
|
(20)
|
(13)
|
|
107
|
|
53
|
57
|
Total Respiratory
|
1,181
|
|
(11)
|
(13)
|
|
1,226
|
|
4
|
4
|
|
1,142
|
|
(7)
|
(4)
|
|
1,362
|
|
19
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
448
|
|
5
|
3
|
|
442
|
|
(1)
|
(1)
|
|
422
|
|
(5)
|
97
|
|
390
|
|
(8)
|
(7)
|
Synagis
|
224
|
|
(4)
|
(4)
|
|
26
|
|
(89)
|
(88)
|
|
164
|
|
n/m
|
n/m
|
|
251
|
|
53
|
n/m
|
Seroquel XR/IR
|
97
|
|
n/m
|
40
|
|
131
|
|
35
|
37
|
|
77
|
|
(41)
|
6
|
|
56
|
|
(27)
|
(31)
|
Losec/Prilosec
|
69
|
|
-
|
(4)
|
|
76
|
|
10
|
11
|
|
67
|
|
(12)
|
85
|
|
60
|
|
(10)
|
(8)
|
Movantik/Moventig
|
28
|
|
(7)
|
(7)
|
|
24
|
|
(14)
|
(14)
|
|
32
|
|
33
|
167
|
|
25
|
|
(22)
|
(22)
|
FluMist/Fluenz
|
-
|
|
n/m
|
n/m
|
|
-
|
|
n/m
|
n/m
|
|
35
|
|
n/m
|
n/m
|
|
75
|
|
n/m
|
n/m
|
Others
|
63
|
|
(62)
|
(45)
|
|
48
|
|
(25)
|
(26)
|
|
35
|
|
(27)
|
n/m
|
|
35
|
|
-
|
31
|
Total Other
|
929
|
|
(15)
|
(16)
|
|
747
|
|
(20)
|
(20)
|
|
832
|
|
12
|
15
|
|
892
|
|
7
|
22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Product Sales
|
4,985
|
|
(9)
|
(11)
|
|
5,030
|
|
1
|
1
|
|
5,266
|
|
5
|
8
|
|
5,768
|
|
10
|
13
|
|
Q1 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q2 2017
$m
|
|
Actual
%
|
CER%
|
|
Q3 2017
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2017
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Tagrisso
|
171
|
|
16
|
19
|
|
232
|
|
36
|
34
|
|
248
|
|
7
|
5
|
|
304
|
|
23
|
22
|
Iressa
|
124
|
|
5
|
8
|
|
137
|
|
10
|
9
|
|
137
|
|
-
|
(1)
|
|
130
|
|
(5)
|
(6)
|
Lynparza
|
57
|
|
(8)
|
(6)
|
|
59
|
|
4
|
2
|
|
81
|
|
37
|
33
|
|
100
|
|
23
|
22
|
Imfinzi
|
-
|
|
-
|
-
|
|
1
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
18
|
|
n/m
|
n/m
|
Calquence
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
3
|
|
n/m
|
n/m
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
214
|
|
(4)
|
(3)
|
|
248
|
|
16
|
15
|
|
241
|
|
(3)
|
(5)
|
|
238
|
|
(1)
|
(1)
|
Zoladex
|
185
|
|
(21)
|
(12)
|
|
178
|
|
(4)
|
(5)
|
|
185
|
|
4
|
2
|
|
187
|
|
1
|
1
|
Casodex
|
56
|
|
(7)
|
(2)
|
|
54
|
|
(4)
|
(3)
|
|
51
|
|
(6)
|
(9)
|
|
54
|
|
6
|
6
|
Arimidex
|
52
|
|
(9)
|
(7)
|
|
54
|
|
4
|
4
|
|
54
|
|
-
|
(2)
|
|
57
|
|
6
|
6
|
Others
|
26
|
|
(10)
|
(3)
|
|
30
|
|
15
|
7
|
|
29
|
|
(3)
|
(3)
|
|
29
|
|
-
|
3
|
Total Oncology
|
885
|
|
(5)
|
-
|
|
993
|
|
12
|
11
|
|
1,026
|
|
3
|
1
|
|
1,120
|
|
9
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
207
|
|
(13)
|
(13)
|
|
250
|
|
21
|
20
|
|
285
|
|
14
|
11
|
|
332
|
|
16
|
16
|
Brilinta
|
224
|
|
(5)
|
(4)
|
|
272
|
|
21
|
20
|
|
284
|
|
4
|
3
|
|
299
|
|
5
|
5
|
Onglyza
|
154
|
|
3
|
3
|
|
150
|
|
(3)
|
(3)
|
|
127
|
|
(15)
|
(17)
|
|
180
|
|
42
|
42
|
Bydureon
|
153
|
|
8
|
8
|
|
146
|
|
(5)
|
(5)
|
|
128
|
|
(12)
|
(14)
|
|
147
|
|
15
|
15
|
Byetta
|
46
|
|
(16)
|
(16)
|
|
43
|
|
(7)
|
(7)
|
|
39
|
|
(9)
|
(9)
|
|
48
|
|
23
|
23
|
Symlin
|
14
|
|
-
|
-
|
|
11
|
|
(21)
|
(21)
|
|
10
|
|
(9)
|
(9)
|
|
13
|
|
30
|
30
|
Qtern
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
5
|
|
n/m
|
n/m
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
631
|
|
-
|
3
|
|
560
|
|
(11)
|
(12)
|
|
580
|
|
4
|
2
|
|
594
|
|
2
|
2
|
Seloken/Toprol-XL
|
186
|
|
4
|
6
|
|
181
|
|
(3)
|
(4)
|
|
160
|
|
(12)
|
(14)
|
|
168
|
|
5
|
4
|
Atacand
|
75
|
|
(7)
|
(6)
|
|
72
|
|
(4)
|
(5)
|
|
80
|
|
11
|
8
|
|
73
|
|
(9)
|
(6)
|
Others
|
89
|
|
3
|
12
|
|
90
|
|
1
|
(3)
|
|
80
|
|
(11)
|
(12)
|
|
80
|
|
-
|
(4)
|
Total CVRM
|
1,779
|
|
(2)
|
-
|
|
1,775
|
|
-
|
(1)
|
|
1,773
|
|
-
|
(2)
|
|
1,939
|
|
9
|
9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
677
|
|
(9)
|
(7)
|
|
706
|
|
4
|
3
|
|
668
|
|
(5)
|
(7)
|
|
752
|
|
13
|
12
|
Pulmicort
|
337
|
|
17
|
19
|
|
226
|
|
(33)
|
(33)
|
|
242
|
|
7
|
5
|
|
371
|
|
53
|
51
|
Daliresp/Daxas
|
44
|
|
7
|
10
|
|
48
|
|
9
|
9
|
|
53
|
|
10
|
8
|
|
53
|
|
-
|
(2)
|
Tudorza/Eklira
|
37
|
|
3
|
6
|
|
34
|
|
(8)
|
(8)
|
|
37
|
|
9
|
6
|
|
42
|
|
14
|
14
|
Duaklir
|
19
|
|
-
|
-
|
|
16
|
|
(16)
|
(15)
|
|
21
|
|
31
|
18
|
|
23
|
|
10
|
10
|
Bevespi
|
1
|
|
(67)
|
(50)
|
|
3
|
|
n/m
|
n/m
|
|
4
|
|
33
|
33
|
|
8
|
|
100
|
100
|
Others
|
66
|
|
(20)
|
(19)
|
|
66
|
|
-
|
(4)
|
|
67
|
|
2
|
4
|
|
85
|
|
27
|
30
|
Total Respiratory
|
1,181
|
|
(2)
|
(1)
|
|
1,099
|
|
(7)
|
(8)
|
|
1,092
|
|
(1)
|
(3)
|
|
1,334
|
|
22
|
21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
461
|
|
(6)
|
(4)
|
|
595
|
|
29
|
28
|
|
469
|
|
(21)
|
(22)
|
|
427
|
|
(9)
|
(9)
|
Synagis
|
230
|
|
(24)
|
(24)
|
|
70
|
|
(70)
|
(70)
|
|
153
|
|
n/m
|
n/m
|
|
234
|
|
53
|
53
|
Seroquel XR/IR
|
104
|
|
(36)
|
(35)
|
|
135
|
|
30
|
30
|
|
113
|
|
(16)
|
(16)
|
|
156
|
|
38
|
36
|
Losec/Prilosec
|
68
|
|
15
|
18
|
|
68
|
|
-
|
(3)
|
|
66
|
|
(3)
|
(6)
|
|
69
|
|
5
|
5
|
Movantik/Moventig
|
30
|
|
15
|
15
|
|
32
|
|
7
|
7
|
|
30
|
|
(6)
|
(6)
|
|
30
|
|
-
|
-
|
FluMist/Fluenz
|
-
|
|
n/m
|
n/m
|
|
-
|
|
-
|
-
|
|
20
|
|
n/m
|
n/m
|
|
58
|
|
190
|
175
|
Others
|
105
|
|
(48)
|
44
|
|
173
|
|
65
|
n/m
|
|
140
|
|
(19)
|
(21)
|
|
120
|
|
(14)
|
(15)
|
Total Other
|
998
|
|
(24)
|
(22)
|
|
1,073
|
|
8
|
7
|
|
991
|
|
(8)
|
(9)
|
|
1,094
|
|
10
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Product Sales
|
4,843
|
|
(8)
|
(6)
|
|
4,940
|
|
2
|
1
|
|
4,882
|
|
(1)
|
(3)
|
|
5,487
|
|
12
|
12
|
|
Q1 2016
$m
|
|
Actual
%
|
CER
%
|
|
Q2 2016
$m
|
|
Actual
%
|
CER%
|
|
Q3 2016
$m
|
|
Actual
%
|
CER
%
|
|
Q4 2016
$m
|
|
Actual
%
|
CER
%
|
Oncology
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Iressa
|
135
|
|
5
|
5
|
|
135
|
|
-
|
(2)
|
|
125
|
|
(7)
|
(8)
|
|
118
|
|
(6)
|
(4)
|
Tagrisso
|
51
|
|
183
|
200
|
|
92
|
|
80
|
82
|
|
133
|
|
45
|
44
|
|
147
|
|
11
|
11
|
Lynparza
|
44
|
|
22
|
22
|
|
54
|
|
23
|
23
|
|
58
|
|
7
|
7
|
|
62
|
|
7
|
9
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Faslodex
|
190
|
|
3
|
3
|
|
211
|
|
11
|
9
|
|
207
|
|
(2)
|
(2)
|
|
222
|
|
7
|
9
|
Zoladex
|
178
|
|
(10)
|
(8)
|
|
204
|
|
15
|
8
|
|
199
|
|
(2)
|
(2)
|
|
235
|
|
18
|
11
|
Arimidex
|
57
|
|
(5)
|
(5)
|
|
62
|
|
9
|
7
|
|
56
|
|
(10)
|
(13)
|
|
57
|
|
2
|
5
|
Casodex
|
62
|
|
(2)
|
(6)
|
|
63
|
|
2
|
-
|
|
62
|
|
(2)
|
(5)
|
|
60
|
|
(3)
|
(2)
|
Others
|
21
|
|
(22)
|
(22)
|
|
27
|
|
29
|
12
|
|
27
|
|
-
|
4
|
|
29
|
|
7
|
-
|
Total Oncology
|
738
|
|
3
|
3
|
|
848
|
|
15
|
12
|
|
867
|
|
2
|
2
|
|
930
|
|
7
|
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CVRM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Farxiga
|
165
|
|
9
|
10
|
|
211
|
|
28
|
26
|
|
220
|
|
4
|
4
|
|
239
|
|
9
|
9
|
Brilinta
|
181
|
|
4
|
5
|
|
214
|
|
18
|
16
|
|
208
|
|
(3)
|
(2)
|
|
236
|
|
13
|
15
|
Onglyza
|
211
|
|
10
|
12
|
|
191
|
|
(9)
|
(11)
|
|
169
|
|
(12)
|
(11)
|
|
149
|
|
(12)
|
(11)
|
Bydureon
|
135
|
|
(13)
|
(16)
|
|
156
|
|
16
|
14
|
|
145
|
|
(7)
|
(6)
|
|
142
|
|
(2)
|
(1)
|
Byetta
|
62
|
|
(14)
|
(14)
|
|
76
|
|
23
|
21
|
|
61
|
|
(20)
|
(19)
|
|
55
|
|
(10)
|
(10)
|
Symlin
|
5
|
|
(64)
|
(64)
|
|
10
|
|
n/m
|
n/m
|
|
11
|
|
10
|
10
|
|
14
|
|
27
|
27
|
Legacy:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Crestor
|
1,156
|
|
(13)
|
(13)
|
|
926
|
|
(20)
|
(21)
|
|
688
|
|
(26)
|
(26)
|
|
631
|
|
(8)
|
(7)
|
Seloken/Toprol-XL
|
185
|
|
16
|
11
|
|
189
|
|
2
|
-
|
|
185
|
|
(2)
|
(2)
|
|
178
|
|
(4)
|
(2)
|
Atacand
|
71
|
|
(17)
|
(15)
|
|
89
|
|
25
|
22
|
|
74
|
|
(17)
|
(19)
|
|
81
|
|
9
|
14
|
Others
|
121
|
|
(9)
|
(16)
|
|
106
|
|
(12)
|
(11)
|
|
84
|
|
(21)
|
(19)
|
|
86
|
|
2
|
-
|
Total CVRM
|
2,292
|
|
(7)
|
(7)
|
|
2,168
|
|
(5)
|
(7)
|
|
1,845
|
|
(15)
|
(15)
|
|
1,811
|
|
(2)
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Symbicort
|
749
|
|
(13)
|
(12)
|
|
803
|
|
7
|
6
|
|
697
|
|
(13)
|
(13)
|
|
740
|
|
6
|
8
|
Pulmicort
|
310
|
|
13
|
14
|
|
239
|
|
(23)
|
(23)
|
|
224
|
|
(6)
|
(6)
|
|
288
|
|
29
|
31
|
Daliresp/Daxas
|
31
|
|
(3)
|
(3)
|
|
40
|
|
29
|
29
|
|
42
|
|
5
|
5
|
|
41
|
|
(2)
|
(2)
|
Tudorza/Eklira
|
39
|
|
(17)
|
(17)
|
|
48
|
|
23
|
21
|
|
47
|
|
(2)
|
-
|
|
36
|
|
(23)
|
(23)
|
Duaklir
|
13
|
|
8
|
8
|
|
17
|
|
31
|
31
|
|
14
|
|
(18)
|
(18)
|
|
19
|
|
36
|
43
|
Bevespi
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
-
|
|
-
|
-
|
|
3
|
|
n/m
|
n/m
|
Others
|
65
|
|
-
|
(3)
|
|
79
|
|
22
|
18
|
|
86
|
|
9
|
12
|
|
83
|
|
(3)
|
1
|
Total Respiratory
|
1,207
|
|
(6)
|
(6)
|
|
1,226
|
|
2
|
1
|
|
1,110
|
|
(9)
|
(9)
|
|
1,210
|
|
9
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nexium
|
463
|
|
(18)
|
(18)
|
|
562
|
|
21
|
20
|
|
516
|
|
(8)
|
(9)
|
|
491
|
|
(5)
|
(4)
|
Seroquel XR/IR
|
286
|
|
(6)
|
(6)
|
|
283
|
|
(1)
|
(2)
|
|
236
|
|
(17)
|
(16)
|
|
162
|
|
(31)
|
(32)
|
Synagis
|
244
|
|
(11)
|
(11)
|
|
27
|
|
(89)
|
(89)
|
|
104
|
|
n/m
|
n/m
|
|
302
|
|
n/m
|
n/m
|
Losec/Prilosec
|
75
|
|
(3)
|
(4)
|
|
70
|
|
(7)
|
(9)
|
|
72
|
|
3
|
4
|
|
59
|
|
(18)
|
(17)
|
Movantik/Moventig
|
17
|
|
13
|
13
|
|
23
|
|
35
|
35
|
|
25
|
|
9
|
9
|
|
26
|
|
4
|
4
|
FluMist/Fluenz
|
5
|
|
(97)
|
(97)
|
|
6
|
|
20
|
20
|
|
26
|
|
n/m
|
n/m
|
|
67
|
|
n/m
|
n/m
|
Others
|
238
|
|
n/m
|
(31)
|
|
256
|
|
8
|
(87)
|
|
224
|
|
(13)
|
(19)
|
|
202
|
|
(10)
|
n/m
|
Total Other
|
1,328
|
|
(24)
|
(22)
|
|
1,227
|
|
(8)
|
(9)
|
|
1,203
|
|
(2)
|
(3)
|
|
1,309
|
|
9
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Product Sales
|
5,565
|
|
(10)
|
(10)
|
|
5,469
|
|
(2)
|
(3)
|
|
5,025
|
|
(8)
|
(8)
|
|
5,260
|
|
5
|
6
|
Announcement
of first quarter 2019 results and Annual General
Meeting
|
26 April 2019
|
|
Announcement
of first half and second quarter 2019 results
|
25 July
2019
|
|
Announcement
of nine months and third quarter 2019 results
|
24
October 2019
|
|
|
|
|
Future
dividends will normally be paid as follows:
|
|
|
First
interim
|
Announced
with half-year and second-quarter results and paid in
September
|
|
Second
interim
|
Announced
with full-year and fourth-quarter results and paid in
March
|
|
|
|
|
Addresses
for correspondence
|
|||
Registered Office
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2
0AA
UK
|
Registrar and
Transfer Office
Equiniti
Limited
Aspect
House
Spencer
Road
Lancing
West
Sussex
BN99
6DA
UK
|
Swedish Central Securities Depository
Euroclear
Sweden AB
PO Box
191
SE-101
23 Stockholm
Sweden
|
US Depositary
Citibank
Shareholder Services
PO Box
43077
Providence
RI
02940-3077
USA
|
Tel:
+44 (0)20 3749 5000
|
Tel
(Freephone in UK):
0800
389 1580
Tel
(outside UK): +44 (0)121 415 7033
|
Tel:
+46 (0)8 402 9000
|
Tel:
(toll free in the US)
+1
(888) 697 8018
Tel:
(outside the US)
+1
(781) 575 4555
citibank@shareholders-online.com
|
|
AstraZeneca
PLC
|
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|